

































The expression of Suppressor of Cytokine Signalling 
(SOCS), JAK-STAT signalling pathway and cytokine 













Dr. Lesley Bergmeier 
 





Centre for Clinical and Diagnostic Oral Sciences 
Barts & The London School of Medicine & Dentistry 


















This work is dedicated  
to my dear mother, my beloved husband  


















“Except for the help listed in the Acknowledgments, the contents of this PhD thesis are 
entirely my own work. This work has not been submitted, in part or in full, for a degree 
























Abstract: Behçet’s disease (BD) is a chronic, multi systemic, recurrent vasculitis 
disease of unknown aetiology. The clinical manifestations are composed of relapsing 
episodes of recurrent oral ulcers, uveitis, skin lesions and genital ulcers along with 
musculoskeletal and neurological involvement. Pro-inflammatory cytokines are a key 
feature of the disease but the triggers for their induction are not well understood and/or 
controversial. Many cytokines (including IFNγ, IL-12, IL-23, IL-10 and IL-6) activate 
the JAK-STAT signalling pathway which is negatively regulated by Suppressor of 
Cytokine Signalling (SOCS) proteins. Therefore, it was hypothesised that SOCS 
proteins may be dysregulated in BD. 
 
The expression of SOCS 1-3 mRNA and protein was studied in peripheral blood 
mononuclear cells (PBMCs), Neutrophils and buccal mucosal cells (BMC) of BD 
patients and compared with healthy controls (HC) and recurrent aphthous stomatitis 
(RAS) patients. SOCS 1 and 3 were significantly upregulated in PBMCs of BD patients 
compared with HC (p=0.0149; p=0.0007) and there were subtle differences between 
expression in relapsed and symptom free BD (quiet BD). SOCS1 and SOCS 3 also 
significantly upregulated in BMC from oral ulcers of BD compared with HC (both at 
p=0.0001). Cytokines were examined in serum, saliva and culture supernatants from 
stimulated PBMCs. IL-6 were significantly upregulated in the saliva of relapsed BD 
patients compared with HC (p=0.0104) and the capacity for IL-10 secretion from BD 
was compromised. Phosphorylation of STATs, transcription factors RORγt, T-bet and 
48 protein kinases were investigated using a novel PhosphFlow method and by 
microarray analysis. STATs were upregulated in BD and seven novel kinase proteins 
showed differential phosphorylation in BD. 
 
Conclusion: SOCS 1-3 expression has changed in BD patients with differences in 
PBMC and Neutrophil expression between the SOCS proteins. Phosphorylation of 
STATs and several kinases show up-regulation in BD and seven kinases with altered 
phosphorylation states in BD were identified as novel targets for future investigation. 
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Chapter 1: Literature review 
1.1 Behçet’s disease 
Behçet’s disease (BD) is a chronic, multi systemic, recurrent vasculitis disease of 
unknown aetiology. The first description of this disease in medical literature goes back 
to the 5
th
 century BCE, by Hippocrates (460–377 BC). He described an endemic 
condition with painful watery eyes of a chronic character, aphthous ulcers and sores in 
the  mouth, genital sores and fluxes and large pustules  in his Epidemion, book 3, case 7 
(Feigenbaum, 1956). In more modern times, Benediktos Adamantiades, a Greek 
ophthalmologist (1875-1962) reported a case of relapsing iritis with hypopyon, scrotal 
ulcers, oral aphthous and sterile arthritis of both knees and brought these three 
symptoms together as signs of a single disease (Adamantiades, 1931). Therefore, some 
references still call this syndrome, "Adamantiades’ syndrome" or "Adamantiades-
Behçet syndrome. However, the syndrome was internationally recognised as Behçet  
Disease and named after Hulusi Behçet, a Turkish dermatologist (1889 -1948), who 
described the condition as a new disease in 1937, after many years following up his 
three patients suffering  from recurrent oral and genital ulcers, eye and skin diseases 
(Verity et al., 2003). 
 
1.2 BD Diagnosis 
Diagnosis of BD is based on clinical features since there is no diagnostic laboratory test 
so far. There was a variety of diagnostic criteria prior to 1990 which made it difficult to 
compare and analyse the results from different studies. In 1990, the International Study 




914 Behçet's disease patients, from 12 centres in 7 countries with controls from the 
same centres [International Study Group-ISG- for Behçet's Disease, (1990)]. According 
to the proposal of the ISG, diagnosis of BD requires the presence of oral ulceration plus 
any two of genital ulceration, typical defined eye lesions, typical defined skin lesions or 




Recurrent oral ulceration 
Minor aphthous, major aphthous, or 
herpetiform ulceration observed by 
physician or patient, which recurred at 
least 3 times in one 12 month period 
 
Plus two of the following: 
 
Recurrent genital ulceration 
Aphthous ulceration or scarring, observed 
by physician or patient  
Eye lesions 
Anterior uveitis, posterior uveitis, or cells 
in the vitreous humour on slit lamp 
examination; or retinal vasculitis observed 
by ophthalmologist 
Skin lesions 
Erythema nodosum observed by physician 
or patient, pseudofolliculitis, or 
papulopustular lesions; or acneiform 
nodules observed by physician in post-
adolescent patients not on corticosteroids 
 
Positive pathergy test 
Read by physician at 24–48 hours 
performed with oblique insertion of a 20-
gauge or smaller needle under sterile 
conditions 
Table 1.1: International Study Group Criteria for diagnosis of Behçet's disease. 
 
1.3 BD Epidemiology 
BD is a rare disease and mostly affects inhabitants along the ancient Silk Road from 
mediterranean countries to the Middle East and Far East regions located between 




100,000 has the highest prevalence in the world, regions like northern parts of Europe 
and Asia, Africa and Australia has the least frequency (Azizlerli et al., 2003, Altenburg 
et al., 2006, Zouboulis and Kaklamanis, 2003, Deuter et al., 2008). BD is a rare disease 
in the UK with a frequency of 1-2 in 100,000 people (Zouboulis and Kaklamanis, 
2003). The ratio of male to female of BD varies with ethnic origin and the average age 
of disease onset is 30. BD is very rare in children. Kari 2001 studied the clinical 
spectrum of BD in childhood in 10 UK cases with an age range from 1.2-10 years where 
their clinical features were similar to that of adults (Kari et al., 2001).  
1.4 Clinical Symptoms of BD 
The clinical manifestations of BD show a very wide spectrum and can be observed in 
any organ of the body with unpredictable courses of remissions and exacerbations. 
However, the main symptoms of BD are composed of relapsing episodes of recurrent 
oral ulcers, uveitis, skin lesions and genital ulcers. It can also affect musculoskeletal, 
vascular, gastrointestinal and nervous system. Clinical features of BD follow several 
patterns based on ethnic, geographical and individual diversities (Al-Otaibi et al., 2005, 
Krause et al., 2001). For example while gastrointestinal symptoms are hardly seen in 
Turkish and Saudi Arabian patients, they occur in 33% of Thai and 25% of Spanish 
patients (al-Dalaan et al., 1994, Al-Otaibi et al., 2005, Chen and Chang, 2001, Gürler et 
al., 1997). 
 
The symptoms usually appear less severe and recur at longer intervals after the fourth 
decade (Bardak, 1999, Yazici et al., 1984). Mortality also decreases remarkably with 




disease as male patients with early onset tend to have poorer prognosis (Kural-Seyahi et 
al., 2003).  
.  
1.4.1 Recurrent oral ulcerations 
Recurrent oral ulcers are the first symptom of up to 86.5% of all patients with BD (Al-
Otaibi et al., 2005) (Figure 1.1). These lesions are similar to recurrent aphthous 
stomatitis (RAS) and cannot be differentiated from them, however they are more 
numerous, frequent, larger and more painful. All three types of RAS: minor aphthous, 
major aphthous and herpetiform ulceration can be seen in BD. 
 
 
1.4.2 Genital ulcers 
Genital ulcers occur in 60 to 65% of cases, less common than oral ulcers and hardly 
seen as the first symptoms of BD (Krause et al., 1999). In men the ulcers are located 
mostly on the scrotum and in women on the vulva, major and minor labia, cervix, and 
vagina and heal in a few days, leaving scars (Al-Otaibi et al., 2005). The ulcers can also 
exist in the oesophagus, stomach, small intestine and perianal area and sometimes cause  









Figure1. 1: Oral Ulceration in BD (Royal London Hospital with patient consent). 




1.4.3 Cutaneous manifestations 
Cutaneous futures of BD mostly occur in the form of papulo-pustular lesions and 
erythema nodosum-like lesions (Figure 1.2b). Papulo-pustular lesions are found in 40–
70% of the patients. This acne like lesions appears simultaneously on the skin of the 
back, face and chest and change from papules form to pustules in 24-48 hours.  
Erythema nodosum-like lesions are painful purplish nodules which mostly occur on the 
lower extremities (Al-Otaibi et al., 2005). 
 
1.4.4 Pathergy phenomenon 
A Pathergy phenomenon is a non-specific hyper-reactivity of the skin in response to 
trauma from any intercutaneous injection or needle prick in BD. This condition was 
described for the first time by Blobner in 1937 and reviewed by others later (Al-Otaibi 
et al., 2005). Pathergy tests are performed by pricking the skin with a sterile needle or 
intradermal injection of normal saline which cause formation of 1- 2mm papule. The 
papule may remain unchanged or transform in to a 1-5mm pustule containing sterile pus 
at its centre within 24-48 hours and disappear after 4-5 days. In spite of vast 
investigations in immune histopathology of the test, the aetiology is still unknown. A 
positive pathergy test is one of the diagnostic criteria for BD but it has some limitations. 
The test is more specific in some populations around the ancient Silk Road and much 
less in other regions. Furthermore, the pathergy phenomenon is not specific to BD and 
has been reported in other conditions such as pyoderma gangrenosum and Sweet's 
syndrome and even has been positive in some healthy controls. The other limitation that 
decreases the efficacy of the test is problems with standarsing the procedure itself and 





1.4.5 Ocular manifestations 
A variety of eye lesions have been reported in BD such as anterior and posterior uveitis,   
cataract, glaucoma, vitritis, retinitis and panuveitis. Ocular involvement is severe, 
frequent (43%-65% of patients), often bilateral and can compromise rapidly the visual 
function. It is the most common cause of morbidity in BD since it may lead to blindness 
if not treated within five years (Al-Otaibi et al., 2005). 
 
1.4.6 Vascular manifestations 
Vasculitis is one of the basic pathologic conditions of BD with an estimated range of 2-
46% which can affect any size and type of vessels including both arteries and veins (Ko 
et al., 2000) (Fig1.3). The vascular complications may include thrombophlebitis, deep 
vein thrombosis, arterial obstruction and aneurysms. Venous involvement is more 
common (14-39%) than arterial involvement but the later has greater  morbidity since it 
may lead to aneurysm or arterial occlusion (Saadoun et al., 2012). One of the most 
frequent venous involvements is deep vein thrombophlebitis. It occours mostly in the 
lower extremities, superior vena cava, the inferior vena cava and the upper extremities 
respectively (Ko et al., 2000).  Pulmonary artery aneurysm is also seen in the main 
pulmonary arteries or their branches in BD and is a sign of  poor prognosis (Ceylan et 
al., 2010).  
 
1.4.7 Neurological Involvement  
The neurological complications vary from 2.2% to 40% of cases and mostly affect the 
central nervous system (CNS). The most common clinical presentations of CNS 
comprise bilateral  pyramidal  signs,  headache,  mental  disorders  (memory  defects,  




the pyramido-cerebellar  syndrome. Other neurological symptoms such as, meningitis, 
seizures and hemiplegia have been reported (Akman-Demir et al., 1999). 
 
1.4.8 Other clinical implications 
Gastrointestinal (GI) involvement causes abdominal pain, nausea, vomiting, diarrhoea 
and constipation in these patients. The most common form of extra oral involvement of 
GI in BD is mucosal ulcers which mostly affect the ileocecal area and colon. The GI 
manifestations are recurrent even after surgical treatment (Bayraktar et al., 2000). Renal 
involvement in the form of glomerulonephritis, amyloidosis, renal vascular involvement 
and interstitial nephritis were observed in BD. However, considerable variation in 
frequency of renal involvement from 0-55% has been reported (Akpolat et al., 2003). 
Cardiac symptoms such as mitral valve  prolapse  and  dilatation  of  the  proximal  
aorta  were observed  in  50%  and  30%  of  patients  with  BD,  respectively (Morelli 
et al., 1997). Regarding musculoskeletal disease, mono-arthritis is the most common 
form of observed arthritis in BD. Knees, ankles and wrists were the most commonly 
involved joints in these patients. The arthritis in BD is usually temporary and does not 
leave any deformity (Yurdakul et al., 1983). 
1.5 Aetiopathogenesis 
The aetiopathogenesis of BD remains unknown but an autoimmune reaction triggered 
by an infectious or environmental agent in a genetically susceptible individual is the 
most widely accepted hypothesis (Figure 1.3). 
 
1.5.1 Genetic susceptibilities 
There are some strong evidences to support genetic predisposition in BD such as: 




80% of BD patients, positive family history up to 12% of non-Caucasoid patients and 
the results of several extensive genome wide association studies (GWAS) (Al-Otaibi et 
al., 2005, Krause et al., 2001) (Table 1.2). 
 
The major histocompatibility complex (MHC) is a large cluster of genes which resides 
on short arm of chromosome 6 and is divided into class I and II based on their function. 
MHC complex genes are one of the most comprehensively studied regions in the human 
genome because of their important role in autoimmune, infectious and 
 
Figure 1.3: Overview of the aetiopathogenesis of Behçet’s Disease. 
 
inflammatorydiseases and also  in cancer and transplantation. The class I and II MHC 
genes encode human leukocyte antigens (HLAs) which are present on individual tissue 
types and also perform a fundamental role in antigen presentation. The highly polygenic 
and polymorphic characteristics of these genes lead to effective and rapid immune 
response but at the same time many of these polymorphisms are associated with 




cause autoimmune disorders such as multiple sclerosis, arthritis, diabetes, and 
inflammatory bowel disease.  
 
HLAB51 is the most studied gene and by far the strongest associated genetic factor to 
BD. To confirm the genetic effect of the HLA-B5 or HLA-B51 (HLA-B51/B5) allele on 
the risk of developing of BD a systematic review and meta-analysis of case-control 
genetic association study was performed (de Menthon et al., 2009). Data on 4,800 
patients with BD and 16,289 controls was extracted from 78 independent studies 
published between 1975-2007. The results showed a strong association between BD and 
HLA-B51/B5 (Odds ratio=5.78, 95% Confidence Interval(CI) 5.00-6.67) and its 
consistency through different ethnicities (de Menthon et al., 2009). 
 
A recent GWAS study on 311,459 autosomal single nucleotide polymorphisms (SNPs) 
in 1,215 BD cases and 1,278 healthy controls from Turkey again strongly confirmed the 
association of BD with HLA-B51 and also established associations with the 
interleukin10 (IL10) variant and a variant located between the IL23 receptor (IL23R) 
and IL12 receptor β2 (IL12RB2) genes (Table 1-2). IL23 is a pro-inflammatory 
cytokine which stimulates T helper cell proliferation and increases the production of 
inflammatory cytokines such as IL1, IL6, IL17, and TNFα. IL10 is a potent suppressor 
of  inflammatory cytokines such as IL1, IL6, IL12, TNFα and IFNγ which inhibits T 
cell and NK cell activation (Mizuki et al., 2010, Remmers et al., 2010). 
 
Another GWAS study carried out with 320,438 SNPs on 612 BD patients and 740 
healthy controls in Japan found the same results. In a very recent systematic review and 
meta-analyses of observational studies (Maldini et al., 2012) the relationships between 




B51/B5 carriage predominates in males and the association with moderately higher 
frequency of genital ulcers, ocular and skin involvements and less frequency with 
gastrointestinal manifestations. However, the genetic contribution of HLA-B51 was 
responsible for less than 20% of the genetic risk; therefore, other possible genetic 
factors should be considered (Remmers et al., 2010). 
 
 
MICA (MHC class I related chain A) and MICB are genes in the MHC class I region, 
which are polymorphic, do not appear to present peptides or associate with beta-2-
microglobulins.These proteins show homology with classical HLA molecules, but they 
Gene Protein Odds ratio 
HLA B51 Human leukocyte antigen B 51 
3.49 (95% CI* 2.95–
4.12) 
IL23R/IL12RB2 
Interleukin 23 receptor/interleukin 12 
receptor beta 2 
1.28 (95% CI 1.18–
1.39) 
IL10 Interleukin 10 
1.45 (95% CI 1.34–
1.58) 
CPLX1 Complexin-1 
1.16 95% CI 1.07–
1.27 
IL1R2 Interleukin 1 receptor type II 
1.28 95% CI 1.14–
1.44 
STAT4 
Signal transducer and activator of 
transcription 4 
1.27 95% CI 1.13–
1.42 
CCR1 Chemokine (C–C motif) receptor 1 
1.40 95% CI 1.18–
166 
CCR3 Chemokine (C–C motif) receptor 3 
1.29 95% CI 1.15–
1.46 
IL12A Interleukin 12 alpha 
1.63 95% CI 1.30–
2.03 
MICA MHC class I chain-related A 
1.69 95% CI 1.43–
1.99 
Table 1.2: Key genetic susceptibility genes linked to Behçet's disease. Adopted from (Pineton 




are not expressed on normal circulating lymphocytes and have a selective tissue 
distribution,  mostly in  epithelial  cells, endothelial  cells and fibroblasts and act  as 
ligands for cells expressing a common activator natural killer-cell receptor (NKG2D).  
 Several studies suggested an association between BD and the MICA allele; however, 
MICA and HLA-B51 are strongly associated together because they are in linkage 
disequilibrium (Hughes et al., 2005). The recent GWAS by (Remmers et al., 2010) did 
not confirm any independent association between MICA and BD. Other reported genes 
in MHC region which may associate independently with BD are HLA-A26, HLA-B15, 
HLA-B5701 (Piga and Mathieu, 2011). In spite of large studies, genetic susceptibilities 
are not completely able to justify the aetiology of BD since the healthy control group in 
some studies had a high carriage rate (18%) of HLA-B51 too (de Menthon et al., 2009). 
 
1.5.2 Infection 
Antigenic stimuli like Herpes simplex virus (HSV), Streptococcus sanguis and 
microbial Heat Shock Proteins (HSPs) have been also implicated in the aetiology of BD 
(Lehner, 1997, Lehner et al., 1991) which may act as an infective triggering factor 
through a molecular mimicry with tissue antigens such as human heat shock protein 60 
and /or 70. 
 
1.5.2.1 Herpes simplex virus (HSV) 
Initially, in 1937, Behçet proposed a viral aetiology with recognizing intra and extra 
nuclear inclusions in aphthous and hypopyon samples (Al-Otaibi et al., 2005). Early 
studies claimed finding HSV-1 DNA in peripheral blood lymphocytes and monocytes 
and elevated circulating antibodies to HSV-1 patients with BD. HSV DNA has been 




However, they could not find any trace of HSV-1 DNA in oral ulcers of BD (Studd et 
al., 1991). This hypothesis is still controversial since HSV antibody usually exists in 
healthy controls as well and the data on effectiveness of anti-viral therapy is rare 
(Direskeneli, 2001). 
 
1.5.2.2 Streptococcus sanguis 
Investigations carried out on oral microbial flora have become a matter of interest 
because oral ulcers are the first symptom of up to 86.5% of all patients with BD. 
Streptococci especially Streptococcus sanguis are one of the most studied bacteria in 
pathogenesis of BD and several studies have supported this hypothesis. The serum 
antibody titres against oral streptococci strains 113-20, 114-23, and 118-1 isolated from 
BD patient have shown to be significantly higher than control groups (Yokota et al., 
1992). Furthermore, the uncommon oral S. sanguinis serotypes are significantly 
increased in BD patients compared with healthy and disease controls including Vogt-
Harada disease, sarcoidosis and herpes simplex infection (Kaneko et al., 2008). The 
strong delayed type cutaneous hypersensitivity reactions in BD patient in comparison to 
healthy and disease controls have been observed following skin tests against 
streptococcal antigens (Mizushima, 1989). In a study by (Isogai, 2003), BD-like 
symptoms were elicited in experimental gnotobiotic mice after inoculating S. sanguinis 
from BD patients in their traumatised oral tissue. 
 
1.5.3 Immunopathogenic aspects of BD 
The key immunological features of BD are alterations in cytokine levels, increased 
activity of γδ T cells, elevated level of Th1 and Th17 cytokines, increased T- and B-cell 
responses to heat-shock proteins (HSP) and neutrophil hyperactivity. There is also some 




antigens and the perpetuation of this abnormal immune response even in the absence of 
ongoing infection.  
 
1.5.3.1 Heat-shock proteins (HSPs) 
Heat-shock proteins (HSPs) are the most abundant and highly conserved soluble 
intracellular proteins presenting in all cells in a variety of intracellular locations. Under 
stress conditions such as high temperatures, toxins, oxidative conditions and glucose 
deprivation, their levels can increase by three fold. They play an important role as 
molecular chaperones in folding and unfolding of proteins, assembly of multi subunit 
complexes and a variety of other functions including degradation of proteins, thermo 
tolerance and buffering the expression of mutations (Srivastava, 2002). Therefore, they 
protect cells from severe damage and premature death by preventing denaturation and 
degradation of cellular proteins. HSPs can be classified into families based on their 
molecular weight such as HSP60, HSP70 and HSP90. 
Extracellular HSP (eHSP)  
Following stress conditions, HSPs not only activate inside the cells, but also they have 
been found outside the cells participating in signalling pathways and priming cells of 
the immune system (De Maio, 2011) (Figure 1.3). The detection of HSP70, HSP 90, 
HSP 27 and HSP 60 outside the cells has been reported (De Maio, 2011). The exact 
mechanism by which HSP is secreted into the extracellular environment is not fully 
understood but it has been suggested that HSP can leave the cell by two mechanisms: 
passive (secondary to cell death and lysis) and active (a physiological secretory process) 
(Asea, 2005). 
 
The HSP 70 family are one of the most studied classes of HSPs. Recent studies have 




responses by binding non-specifically to receptors such as CD14, TLR2 and 4, CD36 
and 40. It can cause translocation of NF-κB and induce a strong proinflammatory 
response. In addition, it may specifically bind to an antigenic peptide and receptors such 
as CD91 and LOX1 and present the antigenic peptide to MHC class I and II (Asea, 
2008, Asea et al., 2000, Basu et al., 2001, Binder et al., 2000, Delneste et al., 2002, 
Draude et al., 1999).  
 








HSP and BD 
It is widely reported that microbial HSPs could be involved in the pathogenesis of BD 
through cross-reactivity with human HSP which induce proliferation of autoreactive T 
cells, specific to human HSP60 and result in an autoimmune reaction and tissue 
destruction (Lehner, 1999, Pineton de Chambrun et al., 2012). HSP peptides from 
bacteria including S.sanguis have been found in the sera of BD patients (Isogai, 2003). 
Significant sequence homology of about 60% exists between human HSP60 and 
microbial HSP65. Autoantibodies against HSP65 and HSP60 have been reported in BD 
patients. The upregulation of HSP 60/65 expression in mucocutaneous lesions of BD 
patient and increased T- and B-cell responses against mycobacterial and human 60/65 
kDa HSP in BD patients have been reported (Ergun et al., 2001). 
 
Both subcutaneous injection of HSP peptide 336-51with adjuvant and oral and nasal 
administration without adjuvant are able to induce experimental autoimmune uveitis in 
rats (Phipps et al., 2003). In a clinical trial on 8 BD patients, following oral 
administration of p336–351-CTB (peptide conjugated to the mucosal adjuvant, 
recombinant cholera toxin B subunit), with gradual withdrawal of the 
immunosuppressive drugs, no relapse of uveitis was seen in 5 of the patients (Stanford 
et al., 2004).  
(Birtas-Atesoglu et al., 2008), reported a significant upregulation of both free human 
HSP70 and anti-HSP70 antibodies in patients with BD. It was concluded that HSP70 
may mediated innate and adaptive immune responses and participate in 
proinflammatory cytokine activation and tissue destruction in BD.  
 
Although currently HSP is the most studied putative triggering factor in pathogenesis of 




upregulation of autoantibodies against αβ-crystalline have been reported.  This is a 
small stress protein that has been found in cerebral spinal fluid (CSF) and serum of BD 
patients with neurological involvement (Pineton de Chambrun et al., 2012). 
Furthermore, increased immune response to retinal S antigen in BD uveitis has been 
observed (Ermakova et al., 2003). 
 
1.5.3.2 γδ T lymphocytes 
γδ T lymphocytes comprise approximately 5% of T cells population and are highly 
abundant in mucosal tissues. This subset of T cells is defined by their T cell receptors 
(TCR) which are constituted by a γ and a δ chain as opposed to the  and  chains of 
the majority of T cells. γδ TCRs contain a broad specific spectrum of ligand recognition 
including bacterial phospho antigens, non-classical MHC-I molecules and unprocessed 
proteins (Ferreira, 2013). γδ T cells can act as antigen-presenting cells linking innate 
and adaptive immunity, produce a diverse range of cytokines, exert cytotoxic effector 
function and regulates αβ T cells (Al-Otaibi et al., 2005, Ferreira, 2013). 
 
γδ T cells play important roles in mucosal immunity as the first line of host defence. 
Since many common manifestations of BD occur in mucosal regions, γδ T lymphocytes 
have been subject to several investigations in BD. Accumulation of cytotoxic γδ T cells 
in the sites of inflammation including, broncho alveolar lavage CSF and PBMCs of BD 
patient has been reported (Hamzaoui et al., 1994). Moreover, significant γδ T cell 
proliferative responses have been elicited following stimulation with HSP peptides in 
active BD patients (Hasan et al., 1996). Freysdottir et al., 1999 reported significant 
elevated numbers of activated γδ T cells in PBMCs of BD patients compared to RAS 




of the γδ T cells and suggested BD may have been caused by different antigenic stimuli 
or responses which are responsible for the wide clinical heterogeneity of the disease. 
 
Infliximab, an anti-TNFα monoclonal antibody used for treatment of BD patients, was 
able to suppress in vivo and in vitro γδ T cells expansion, activation and cytotoxic 
activity. This mechanism may explain its effectiveness in BD patient (Pineton de 
Chambrun et al., 2012). Overall, γδ T cells seem to play a role in pathogenesis of BD 
but more studies need to clarify the exact mechanism. 
 
1.5.3.3 Neutrophil hyperactivity 
Neutrophils are the most abundant leucocytes which play a crucial role in innate 
immune response. They are the first immune cells appear in the site of inflammation 
following infection or trauma and function as phagocytes. Inappropriate activation of 
neutrophils leads to tissue damage and inflammation progression. The implication of 
neutrophils in pathogenesis of Behçet’s disease has been reported by several studies. 
(Eksioglu-Demiralp et al., 2001) showed neutrophil hyperactivity in BD by presenting 
data on increased expression level of surface markers such as CD11a, CD10, and CD14 
associated with activated neutrophils. Additionally, the upregulation of reactive oxygen 
species (ROS) in BD have been observed (Yazici et al., 2004). Histopathological 
analysis of BD lesions also indicated the vascular infiltration of neutrophils (Kobayashi 
et al., 2000). 
 
The exact mechanism of neutrophil activation is still unknown. However, the raised 
level of IL-6, IL-8, IL-18 and TNF-α may cause the retaining of a “primed” state of 




1.5.3.4 Cytokines and BD 
Cytokines are small, secreted, signalling proteins which are produced in response to 
antigens by variety of cell types including macrophages/monocytes, dendritic cells, 
lymphocytes, neutrophils, endothelial cells and fibroblasts. They are usually produced 
temporarily and are potent even at picomolar concentrations. They interact with specific 
cell surface receptors to increase or decrease expression of membrane proteins, 
proliferation and secretion of effector molecules (Abbas AK, 2003). Cytokines interact 
in a network by inducing each other, transmodeling cell surface receptors, and by 
synergic, additive, or antagonistic interactions on cell function (Balkwill and Burke, 
1989). Appropriate cytokine production leads to protective immunity while 
inappropriate cytokine production causes tissue destruction and disease progression. 
Therefore, the cytokine network plays an important role in the onset, progression and 
tissue damage in inflammatory diseases. They are regulators of host responses to 
infection, immune responses, inflammation, and  trauma. Some cytokines act to make 
disease worse (proinflammatory), whereas others serve to reduce inflammation and 
promote healing (anti-inflammatory). Considerable attention has also been given to 
blocking cytokines, which are harmful to the host, particularly during overwhelming 
infection. The study of cytokines implicated in the pathogenesis of BD provides 
important information on finding diagnostic or activity markers and new therapies.  
Cytokines involved in pathogenesis of BD can be categorized into proinflammatory 
cytokines and chemokines, Th1 type, Th2 type and Th17 type cytokines. 
 
1.5.3.4.1 Pro-inflammatory cytokines 
Pro-inflammatory cytokines, including IL-1α, IL-1β, IL-6 and TNF-α, play major roles 
in innate and adaptive immune responses and promote inflammatory reactions in target 




and their products.  Several studies have confirmed the elevated levels of IL-1α, IL-1R, 
and IL-1β in the serum of patients with BD (Zhou et al., 2012, Düzgün et al., 2005). 
However, there were no significant differences in the serum levels of these cytokines 
and their inhibitors between active and inactive patients. Significant association of IL‐
1A −889 polymorphism with increased susceptibility for BD has been reported in a 
study done on 132 BD patients and 105 healthy in Turkey (Karasneh et al., 2003).  
 
TNF-α is one of the most studied cytokines in BD. The role of TNF-α in BD 
pathogenesis is supported by several studies confirming its therapeutic effectiveness in 
BD. A significantly higher serum level of TNF-α and its soluble receptor (TNFR1) were 
observed in patients with active BD in comparison to controls (Düzgün et al., 2005). 
Besides, high levels of TNF-α were found in the aqueous humor from patients with 
uveitis (Santos Lacomba et al., 2001). In another study, (Ahmad et al., 2003), 
association of TNF-1031C allele with susceptibility to BD in Caucasoid patients was 
observed. A recent meta-analysis study of TNF polymorphisms showed association of -
1031C, -238A and the -857T promoter polymorphisms with BD in various ethnic 
groups (Touma et al., 2010). 
 
The association of IL-6 with disease activity in Neuro-BD has been verified by several 
studies (Zhou et al., 2012). In a study done on Neuro BD patients, a significant elevated 
level of IL-6 in CSF was found. It suggested IL-6 as a disease activity marker along 






1.5.3.4.2 Th1 type cytokines 
Th1 cells are responsible for directing cell mediated immunity by releasing cytokines 
such as interferon-γ (IFN-γ) and IL-12. Most of the studies are in favour of Th1 
polarization of the immune response in Behçet’s disease (Frassanito et al., 1999, Zhou 
et al., 2012). Ben Ahmed et al., 2004  reported the significant upregulation of IL-12 and 
IFN-γ mRNA expression level in BD mucocutaneous lesions compared with controls. 
In a study by (Ahn et al., 2006), cytokine profiles in the aqueous humour of BD patients 
with uveitis were investigated. They observed higher level of IFN-γ in BD uveitis in 
contrast to higher concentrations of IL-4 in patients without Behçet’s uveitis, suggesting 
a strong Th1 polarization in Behçet’s uveitis (Ahn et al., 2006). The recent GWAS 
studies also revealed the association of IL23R-IL12RB2 variants with BD (Mizuki et 
al., 2010, Remmers et al., 2010). However, some studies reported higher serum level of 
IL-4, IL-10 and IL-13 and lower level of IL-12 and IFN-γ in active BD patients 
compared to inactive BD, recurrent aphthous stomatitis, and healthy controls. They 
concluded a complex cytokine profile Th1/Th2 cell type in BD (Raziuddin et al., 1998, 
Aridogan et al., 2003). IL-18 promotes a Th1 response by stimulating the secretion of 
IL-12 and INF-γ and suppression of IL-10. Therefore, the elevated level of IL-18 in the 
serum of BD patient supported the hypothesis of a cell mediated immunity nature in BD 
(Musabak et al., 2006, Oztas et al., 2005).  
 
1.5.3.4.3 Th2 type cytokines 
Th2 cells are responsible for promoting humoral immunity by producing IL-4, IL-5, IL-
13 and IL-10. IL-10 is a potent anti-inflammatory cytokine with an inhibitory role on 
Th-1cytokines, proinflammatory cytokines, antigen presenting cells and B-cell 
proliferation which results in humoral immunity promotion. IL-10 is the most well 




of BD, the study by (Ben Ahmed et al., 2004) revealed increase level of IL10 and 
unchanged IL-4 level. The association of BD with IL-10 gene was confirmed and 
validated in different GWAS studies (Mizuki et al., 2010, Remmers et al., 2010, 
Wallace et al., 2007, Xavier et al., 2012). Remmers (2010) also reported the association 
of IL-10 variant (the rs1518111 A allele) with reduction in both its mRNA and protein 
level expression in BD. Overall, there is no data regarding the possible role of IL-4, IL-
5 and IL-13 in BD.  
 
1.5.3.4.4 Th17 type cytokines 
Th17 cells are a subset of T cells characterized by the secretion of IL-17. They have 
been implicated in the pathogenesis of a variety of immune mediated diseases such as 
inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis and periodontal 
disease.  Th-17 cells are differentiated from naïve CD4
+
 T cells in the presence of TGF-
β and IL-6 in mouse model studies (Bettelli et al., 2006, Mangan et al., 2006, Veldhoen 
et al., 2006). Tumour necrosis factor-α (TNF-α) and IL-1β can also induce mouse Th17 
differentiation, but only in the presence of TGF-β and IL-6 (Nakae et al., 2007, Sutton 
et al., 2006, Veldhoen et al., 2006). Besides, since IL-23 receptors are only expressed 
on activated T cells, they are unable to induce a Th17 differentiation of naïve T cells but 
can induce upregulation of IL-17 in memory T cells. In humans IL-6 and IL-23 induce a 
small amount of IL-17 alone and greatly enhance Th17 differentiation in the presence of 
IL-1β (Acosta-Rodriguez et al., 2007, Wilson et al., 2007). 
 
IL-17 is a proinflammatory cytokine which induces the production of IL-1, TNF -α, IL-
6 and IL-8. Interestingly, besides Th-17 cells, IL-17 can also be produced by CD81
+
 T 
cells, γδ T cells, natural killer T (NKT) cells, neutrophils, and eosinophils. IL-17 




inflammation.Th17 cells express the chemokine receptor CCR6, which mediates 
homing to skin and mucosal tissues and has been shown to play an important role in 
recruitment of pathogenic T cells in many inflammatory diseases associated with IL-17 
such as psoriasis, inflammatory bowel diseases, allergic asthma and rheumatoid arthritis 
(Hirota et al., 2007, Lundy et al., 2005, Ruth et al., 2003, Teraki et al., 2004). 
 
In BD patients, upregulation of neutrophil activation associated with increased CXCL8 
(IL-8) production have been reported (Kurauchi et al., 2005) .Besides, elevated levels of 
IL-6, IL-1β, IL-8 and TNF-α which are involved in differentiation of naïve CD4
+
 T cells 
to TH-17, have been observed (Akman-Demir et al., 2008, Fossiez et al., 1996). In a 
study on BD patients with active uveitis the upregulation of IL-23, IL-17, IFN-γ have 
been shown in addition to the increased frequency of IL-17 and IFN-γ producing cells in 
PBMCs (Chi et al., 2008). The elevated serum levels of IL-17A in active BD patients 
have been observed suggesting the important role of IL-17 in acute attacks of the 
disease (Ekinci et al., 2010). 
 
In a recent study on Behçet`s uveitis and folliculitis, in addition to showing the 
importance of Th-17 cells, the significant increase in the Th17/Th1 ratio in these 
patients compared to healthy controls have been reported (Kim et al., 2010). Moreover, 
Chi (2008) presented data on the significant elevated levels of IL-23p19 mRNA 
expression, IL-23, IL-17, and IFN-γ in BD patients with active uveitis. They also 
reported increased frequencies of IL-17-producing and IFN-γ- producing T cells in 
PBMCs of active BD patients with uveitis. Additional evidence for the possible role of 
IL17 in the pathogenesis of BD has arisen from GWAS studies on IL-23 which reported 
the strong association of IL-23 receptor (IL-23R) genes with BD (Mizuki et al., 2010, 




polymorphisms of IL23R and IL17 and BD (Jiang et al., 2010, Kim et al., 2012). On the 
other hand, an investigation of BD patients with gastrointestinal involvement, a Th1 
pattern, not a Th17, has been reported (Ferrante et al., 2010).  
1.5.3.4.5 Chemokines 
Chemokines are small cytokines (approximately 8-10 kilodaltons in size) which are well 
known for their chemotactic function in immune system. They cause attraction of 
monocytes and dendritic cells (DCs) to the sites of inflammation, directing them to 
lymphatic vessels, leading to T cells and APCs through lymphatic drainage organs. 
They also play a role in T-cell homing. Furthermore, several evidences suggest some 
chemokines such as CCL2 and CCL3 are involved in direction of T cell differentiation 
(Luther and Cyster, 2001). IL-8, also known as neutrophil chemotactic factor, is the 
most studied chemokine in BD. (Gür-Toy et al., 2005) found a correlation between high 
serum levels of IL-8 and the increased number of clinically involved organs and 
suggested IL-8 as a disease serologic activity marker. Besides (Durmazlar et al., 2009) 
observed that the elevated levels of IL-8 in BD is more prominent in patients with 
vascular involvement than other involved organs. It concluded that serum IL-8 levels 
may be considered as a maker for vascular involvement. However, the study on German 
and Turkish cohort did not find any correlation between susceptibility to BD and 
polymorphism in IL-8 and IL-8R genes (Zhou et al., 2012). 
1.6 Treatment  
The main goal in effective treatment of BD is to prevent irreversible damage to the vital 
organs particularly in high risk patients such as young men and to prevent exacerbations 
of mucocutaneous and joint involvement. These do not usually cause serious harm but 
affect patients quality of life (Hatemi et al., 2008). In 2008, a  multidisciplinary expert 




guidance for the management of Behçet’s disease and suggested nine recommendations 
for the management of different aspects of BD (Hatemi et al., 2008)(Table 1.3). 
However, the differences in health care systems, the economic status of different 




Any patient with BD and inflammatory eye disease affecting the posterior segment should 
be on a treatment regime that includes azathioprine and systemic corticosteroids. 
2 
If the patient has severe eye disease defined as >2 lines of drop in visual acuity on a 10/10 
scale and/or retinal disease (retinal vasculitis or macular involvement), it is recommended 
that either cyclosporine A or infliximab be used in combination with azathioprine and 
corticosteroids; alternatively IFNα with or without corticosteroids could be used instead. 
3 
There is no firm evidence to guide the management of major vessel disease in BD. For the 
management of acute deep vein thrombosis in BD immunosuppressive agents such as 
corticosteroids, azathioprine, cyclophosphamide or cyclosporine A are recommended. For 
the management of pulmonary and peripheral arterial aneurysms, cyclophosphamide and 
corticosteroids are recommended. 
4 
Similarly there are no controlled data on, or evidence of benefit from uncontrolled 
experience with anticoagulants, antiplatelet or anti fibrinolytic agents in the management 
of deep vein thrombosis or for the use of anticoagulation for the arterial lesions of BD. 
5 
There is no evidence-based treatment that can be recommended for the management of 
gastrointestinal involvement of BD. Agents such as sulfasalazine, corticosteroids, 
azathioprine, TNFα antagonists and thalidomide should be tried first before surgery, 
except in emergencies. 
6 In most patients with BD, arthritis can be managed with colchicine. 
7 
There are no controlled data to guide the management of CNS involvement in BD. For 
parenchymal involvement agents to be tried may include corticosteroids, IFNα, 
azathioprine, cyclophosphamide, methotrexate and TNFα antagonists. For dural sinus 
thrombosis corticosteroids are recommended. 
8 
Cyclosporine A should not be used in BD patients with central nervous system 
involvement unless necessary for intraocular inflammation. 
9 
The decision to treat skin and mucosa involvement will depend on the perceived severity 
by the doctor and the patient. Mucocutaneous involvement should be treated according to 
the dominant or co dominant lesions present. 
 
Topical measures (ie, local corticosteroids) should be the first line of treatment for isolated 
oral and genital ulcers. 
 
Acne-like lesions are usually of cosmetic concern only. Thus, topical measures as used in 
acne vulgaris are sufficient. 
 
Colchicine should be preferred when the dominant lesion is erythema nodosum. 
 
Leg ulcers in BD might have different causes. Treatment should be planned accordingly. 
 
Azathioprine, IFNα and TNFα antagonists may be considered in resistant cases. 





1.7 JAK-STAT (Janus kinase signal transducers and activators of 
transcription) pathway 
The majority of cytokines, expressing type I and type II cytokine receptors, mediate 
their responses through activation of the JAK/STAT signalling pathway.  This pathway 
was uncovered for the first time through a study on transcriptional activation in 
response to interferons (Darnell et al., 1994). The JAK-STAT pathway comprises JAK 
(Janus kinase) and STAT (signal transducers and activators of transcription) (Figure 
1.5). The JAK-STAT pathway plays an important role in mediating the effect of most 
cytokines in immunoregulation, host defence and immunopathology (Darnell et al., 
1994, Leonard and O'Shea, 1998, O'Shea and Murray, 2008).  
 
JAKs constitute a family of non-receptor, intracellular tyrosine kinases including JAK1, 
JAK2, JAK3 and TYK2 which are associated with intracellular domain of cytokine 
receptors. They selectively phosphorylate and activate STATs. JAKs are protein kinases 
of 120-140 KDa and constitute seven regions of a high homology called Janus 
homology domains 1 to 7 (JH1-7). JH1 is the kinase domain, containing two tyrosine 
molecules which are phosphorylated following stimulation by a ligand. JH2 is the 
pseudo-kinase domain which lacks enzymatic activity but is required for JH1 catalytic 
activity. JH3–JH4 region shares some similarity with Src-homology-2 (SH2) domains. 
JH4–JH7 region constitutes a FERM domain (Four-point-one, Ezrin, Radixin, Moesin) 
which mediate protein–protein interactions. The JH6 and JH7 domains mediate the 





Figure 1.5: JAK-STAT pathway. a) JAK-STAT signalling pathway.  b) The domain structure 
of JAKs.  c) The domain structure of STATs (Adapted from Shuai and Liu; 2003). 
 
STATs are a family of transcription factors hidden in the cytoplasm and consist of 
seven structurally and functionally related proteins: STAT1, STAT2, STAT3, STAT4, 
STAT5a, STAT5b and STAT6. All STATs family members constitute six conserved 
domains: N-terminal domain, Coiled-coil domain, DNA-binding domain, Linker 
domain which connects the DNA-binding domain with the SH2/dimerization domain, 




dimerization of STATs, and transcriptional activation domain (Kisseleva et al., 2002, 
Shuai and Liu, 2003) (Figure 1.5).  
 
Generally, JAK-STAT pathway signalling comprises three components: Cytokine 
receptor, JAK protein and STATs. Binding a cytokine to its receptor induces 
conformational changes of the receptor chains and subsequent activation of the JAK 
family of kinases which are constitutively associated with the receptor. Then, the 
activated JAKs phosphorylate specific tyrosine motifs on the cytoplasmic tails of the 
receptor which act as docking sites to recruit and phosphorylate STATs through their 
SH2 domains.  Activated STATs then dimerize and are subsequently released from the 
receptor and translocate to the nucleus where they activate gene transcription (Kisseleva 
et al., 2002, Shuai and Liu, 2003) (Figure 1.5). 
 
The human genetic studies have suggested several evidences to support the implication 
of this pathway in human diseases. The association of polymorphisms of genes 
encoding different parts of signalling pathways of cytokines such as IL-12A, IL-6 and 
IL-23 with autoimmune disease has been presented in Figure 1.6. The implication of  
STAT3, which is also activated by IL-6 and its receptors, in multiple sclerosis, asthma, 
rheumatoid arthritis and cardiovascular diseases has been reported (O'Shea and Plenge, 
2012).The association of several genes in IL-12 pathway (IL12A, IL-12R and STAT4) 
with primary biliary cirrhosis, systemic sclerosis, systemic lupus erythematosus, 
rheumatoid arthritis, celiac disease and Behçet has been reported by several GWAS 
studies (O'Shea and Plenge, 2012). Furthermore, polymorphisms of the genes encoding 
both subunits of IL-23 (IL23A and IL12B), JAK2, TYK2, and STAT3 have all been 
linked to autoimmune diseases such as psoriatic arthritis, Grave’s disease, Crohn’s 




Figure 1.6: GWAS study results on association of genetic factors links of JAKs-STATs related 
cytokine signalling with human diseases. Adapted from (O'Shea and Plenge, 2012).  AS, 
ankylosing spondylitis; IBD, inflammatory bowel disease; PBC, primary biliary cirrhosis; SLE, 
systemic lupus erythematosus. 
 
Therefore, cytokine signalling pathways are strongly regulated to avoid excessive 
immune responses and pathogenic consequences in the host. So far, three distinct 
negative regulation mechanisms have been found. These  include protein tyrosine 
phosphatases inhibitors such as SHP-1 and CD45, the protein inhibitors of activated 
STATs (PIAS) and the suppressor of cytokine signalling (SOCS) proteins (Krebs and 










1.8 Suppressor of Cytokine Signalling (SOCS) proteins 
           
One of the mechanisms which negatively regulate cytokine signalling pathways is a 
family of intracellular proteins called SOCS proteins. They regulate cytokine signalling 
by inactivation of the Janus kinase (JAK), blocking access of the STAT proteins to 
receptor binding sites, and ubiquitination of signalling proteins. SOCS proteins are also 
involved in a variety of other biological processes such as regulation of macrophage and 
dendritic-cell activation and T-cell development, differentiation and function. Several 
lines of research supported the implication of SOCS dysregulation in diseases of the 
immune system. Nevertheless, SOCS proteins may be activated by other stimulants 
such as lipopolysaccharide (LPS), isoproterenol, statins and cyclic AMP (cAMP). 
Therefore, they play a role in many other immunological processes (Yoshimura et al., 
2007) . 
 
1.8.1 The structure and function of SOCS proteins  
SOCS family comprises eight members: CIS (Cytokine Inducible SH2 containing 
protein) and SOCS1–SOCS7. They contain three defined regions: a central SH2 
domain, an amino-terminal domain of variable length and divergent sequence and a 
carboxy-terminal 40-amino-acid module called SOCS box (Yoshimura et al., 2007)(Fig. 
1.6). 
 
The SOCS proteins bind to their targets by the central SH2 domain. The SH2 domain of 
SOCS1 directly binds to the activation loop of JAKs while the SH2 domains of CIS, 
SOCS2, and SOCS3 bind to phosphorylated tyrosine residues of stimulated cytokine 
receptors (Tamiya et al., 2011). Moreover, SOCS1 bind directly to the type I IFN 






Figure 1.7:  SOCS function adapted from (Yoshimura et al., 2012). 
 
 The SOCS box recruits the ubiquitin-transferase system for proteasomal degradation. 
The SOCS box interacts with elongin B and elongin C, cullin-5 and RING-box-2 
(RBX2) to recruit E2 ubiquitin transferase 8. It has been postulated that SOCS-box-
containing molecules such as CIS–SOCS-family proteins, possibly act as E3 ubiquitin 
ligases and mediate proteins degradation through their N-terminal regions (Yoshimura 
et al., 2007).  
 
SOCS1 and SOCS3 are strong inhibitors of JAKs as their structure contains an extra 




SOCS1 and 3 to inhibit the tyrosine kinase activity of JAK directly.  SOCS1 mediates 
its inhibitory function on JAKs by binding to the activation loop of its catalytic domain 
using both KIR and SH2 domains (Yoshimura et al., 2007). Most of the receptors which 
are activated by STAT3 are specifically inhibited by SOCS3. SOCS3 also inhibits the 
IL-12-induced STAT4 activation pathway (Yoshimura et al., 2007). 
 
 
Figure 1.8: SOCS Structure. Adapted from (Yoshimura et al., 2007). 
 
Cytokine-inducible SH2 (CIS) is the first member of SOCS family which was identified 
by Yoshimura et al., (1995). In vivo studies on CIS transgenic mice suggested CIS as a 
specific inhibitor of the STAT5 pathway (Matsumoto et al., 1999). SOCS1 was first 
identified by three research groups with different approaches (Yoshimura et al., 2012). 
 
1.8.2 The role of SOCS proteins in innate immunity 
The regulation of innate immunity following activation of TLRs by pathogens is crucial 
as any excessive responses cause damage to host tissue. Since TLR ligands, such as 
LPS are potent inducers of SOCS, it has been postulated that SOCS1 and SOCS3 
proteins negatively regulate TLR signalling pathways (Naka et al., 2005). Several 
studies have reported upregulation of pro-inflammatory cytokines such as TNF, IL-12 
and IFNγ, and nitric oxide in response to TLR of macrophages, DCs and fibroblasts of 




has been revealed that SOCS1-deficient mice are oversensitive to LPS-induced shock, 
causing  a surge in inflammatory cytokines such as tumour-necrosis factor (TNF) and 
IL-12 production, conversely, introducing SOCS-1 inhibited NF-kappaβ and STAT1 
activation in macrophages (Nakagawa et al., 2002, Yoshimura et al., 2007). 
 
Regarding the mechanism, some studies support the possible direct effect of SOCS1 on 
some components of TLR–NF-κB (nuclear factor-κB) signalling pathway. It has been 
suggested that SOCS1 may bind to p65 subunit of NF-kB or MyD88-adaptor-like 
protein (MAL), providing for their ubiquintination and degradation (Yoshimura et al., 
2007).  
 
Contrary to SOCS1, the role of SOCS3 in innate immunity is more complicated. SOCS3 
might play an important role in regulation of opposing activity of IL-6 and IL-10 in 
macrophages following stimulation with LPS but there are some contradictory reports.  
 
SOCS3 inhibited IL-6 signalling through binding to the IL-6R subunit gp130 (Tyr759) 
(Yoshimura et al., 2007). Several studies reported the inhibitory function of SOCS3 on 
IL-6 but not IL-10 activated by STAT3 in primary human macrophages (Niemand et al., 
2003, Yasukawa et al., 2003). It has been suggested that, when SOCS3 action is 
blocked, macrophages appear to be hypersensitive to the anti-inflammatory properties 
of IL-6, therefore, SOCS3 shows a critical role in inhibiting IL-6 signals and inducing 
immune responses to control for example in T.gondii infection (Whitmarsh et al., 2011). 
In contrast, mice lacking SOCS3 developed severe histopathological symptoms such as 
increased numbers of neutrophils in the inflamed synovium, bone marrow, peripheral 





1.8.3 Role of STATs and SOCS proteins in Th-cell differentiation 
Naïve CD4+ T cells, following interaction with their cognate antigen, can differentiate 
into at least four major lineages of T helper (Th) cells Th1, Th2, Th17 and inducible T 
regulatory (iTreg) cells. They are defined based on their distinct cytokine production 
profiles and their functions. Particular cytokines environment and transcription factors 
are key elements in determining CD4 T cell fates and effector cytokine production 
(Figure1.9). 
 
Th1 cells, which are developed to increase immune responses to intracellular pathogens, 
are characterized by IFN-γ production, a potent activator of cell-mediated immunity. 
Th1 polarization is mainly induced by IL-12 and IFN-γ through STAT4 and STAT1/T-
bet pathway (Figure1.9).  
 
Th2 cells, which evolved to eliminate parasitic infections by production of IL-4, IL-5, 
and IL-13, are potent activators of B-cell and humoral responses. Th2 polarization is 
mainly induced by IL-4 through STAT6/GATA-3 path. Any disregulation in Th1 
responses to self-antigens or commensal floral can give rise to tissue destruction and 
chronic inflammation, while disregulation in Th2 responses lead to allergy and asthma. 
 
SOCS1 and SOCS3 play an important role in Th1 and Th2 cell differentiation. SOCS1 
has been shown as a negative regulator of IL-12, IFN-γ and STAT 4 signalling pathway 
through acting as a pseudo-substrate for JACK2 (Eyles et al., 2002). Therefore, as 
predicted, the removal of SOCS1 in CD4+ T cells enhances IFN-γ and STAT4  and 
subsequently Th1 cells production, whereas overexpression inhibits it (Eyles et al., 
2002) (Figure1.9). Moreover SOCS1 deletion leads to IFN-γ and IL-12 production and 




The reported data on the role of SOCS3 in Th1 and Th2 cell differentiation is complex. 
SOCS-3 prevents IL-12-induced STAT4 activation by binding to STAT4 docking site, 
Tyr-800 on the IL-12 receptor β2 chain (Yamamoto et al., 2003) . It seems that deletion 
of SOCS3 in T cells, suppresses both Th1 and Th2 cell responses and it has been 
suggested that this inhibition might not be the result of a direct effect on the 
differentiation of Th1 and Th2 cells but it is because of the increased levels of the 
immunosuppressive cytokines TGF-β and IL-10 (Kinjyo et al., 2006).  
 
Th17 cells are characterized by IL-17A, IL-17F, IL-22, and IL-21 secretion and play 
crucial roles in autoimmunity and inflammation in response to extracellular bacterial 
and fungal pathogens particularly at mucosal surfaces. The Th17 differentiation is 
primarily driven by IL-6, IL-23 and TGF-β through the STAT3/ RORγt pathway. 
Involvement of two signalling pathways: TGF-β-SMAD and JAK-STAT signalling, 
induces distinct Th17 and Treg cell lineages from Th1 and Th2 cells. It has been 
reported that IL-6, IL-21 and IL-23 induce RORγt through STAT3 signalling pathway. 
Moreover, it has been demonstrated that while SOCS3 inhibits STAT3 signalling, its 
blocking causes increased production of Th17 cells (Palmer and Restifo, 2009). Unlike 
SOCS3, the deletion of SOCS1 results in decreased Th17 cell production, and the 
reducing of Th17-mediated diseases (Tanaka et al., 2008).  
 
Regulatory T (Treg) cells (Tregs) are defined by the expression of CD4, CD25 and play 
important role in maintaining peripheral tolerance, preventing autoimmune diseases 
such as type 1 diabetes, limiting chronic inflammatory diseases such as asthma and 
inflammatory bowel disease (IBD) and anti-tumour immunity (Vignali et al., 2008). 
Forkhead box P3 (FOXP3) is  key transcription factor, for  development, maintenance 




Treg polarization is primarily driven by IL-2 and TGF-β through STAT5 /Foxp3 
pathway (Figure1.9). The role of SOCS family in Treg cell differentiation has not been 
well established. It has been suggested that SOCS1 and SOCS3 might prevent the 
differentiation of Treg cells, but more investigation is required (Palmer and Restifo, 
2009)( Figure 1.9).  
 
 
Figure 1.9: Possible roles for SOCS proteins in T cell differentiation. Adopted from 
(Yoshimura et al., 2012). 
 
The role of Treg cells in BD has been investigated by a few studies. In a study on 
Occular BD, the percentages of Treg cells in CD4+Tcells from BD with ocular 
complications were significantly decreased before the ocular attack compared with 
those after ocular attack and normal controls (Nanke et al., 2008). In a recent study, the 
percentage of CD4+CD25+FOXP3+Treg in active patients was found lower than 
clinically inactive patients and healthy controls. Furthermore, there was no difference 
between  the percentage of CD4+CD25+Treg in active and inactive patients and healthy 




1.8.4 SOCS and Behçet’s disease 
Cytokines play a pathologic role in BD. Several cytokines implicated in BD such as 
IFNγ, IL-12, IL-23, IL-10 and IL-6 exerts their effect through activation of JAK-STAT 
signalling pathway which is negatively regulated by SOCS proteins. SOCS proteins are 
also involved in a variety of other biological processes such as regulation of 
macrophage and dendritic-cell activation and T-cell development, differentiation and 
function. Therefore, the implication of SOCS disregulation in diseases of immune 
system such as BD should be considered. 
 
In vivo studies with gene-disrupted or transgenic mice have supported the crucial role of 
SOCS proteins in regulating immune and inflammatory responses. The studies of 
SOCS1- deficient mice have revealed the significant role of SOCS1 in innate immunity 
and pathogenesis of inflammatory and autoimmune diseases (Fujimoto et al., 2004). 
Mice deficient in SOCS1 signalling develop severe skin and eye lesions through the 
recruitment of Th1 and Th17 cells into these non-lymphoid tissues (Yu et al., 2008). In 
another study, the role of SOCS3 in keratinocyte function was investigated using 
keratinocyte-specific SOCS3 gene deficient mice which developed  a severe form of 
skin inflammation (Uto-Konomi et al., 2012). Their results show that skin homeostasis 
is strictly regulated by the IL-6-STAT3-SOCS3 axis.  Eye and skin lesions are also 
characteristic of Behçet’s disease. Therefore, a dysfunction of SOCS proteins may 
associate with the development of inflammatory diseases including BD. 
At present, data regarding the expression and possible implication of SOCS proteins in 
Behçet’s disease are very limited. In a recent study, the expression of Th17 related 
cytokines and their signalling molecules were investigated in PBMC and skin lesions of 
patients with BD (Shimizu et al., 2012). They found a significant rise in TGFβ receptor 




of SOCS in unstimulated cells were not measured. SOCS3 positively regulates TLR4 
signalling by feedback inhibition of TGF-β/Smad3 signalling (Liu et al., 2008) and has 
been shown to influence Th17 cells.  
 
1.9 Phosphorylation and Protein Kinases  
Protein phosphorylation is the most ubiquitous post-translational modification that 
occurs in biology and plays an important role in most signalling processes. It can be 
regarded as a binary switch where addition or removal of phosphate groups will either 
turn on or turn off specific reactions. Identification of site-specific phosphorylated 
substrates is fundamental for understanding the molecular mechanisms of many signal 
transduction pathways. Analysing the phosphorylation profiles of protein kinase 
enzymes and their protein substrates is essential for understanding how cells recognise 
and respond to their environment and any changes that occur within the environment. 
The human genome contains about 500 protein kinase genes and they constitute about 
2% of all human genes. Up to 30% of all human proteins may be modified by kinase 
activity, and kinases are known to regulate the majority of cellular pathways, especially 
those involved in signal transduction (Manning et al., 2002). Analysis of kinase activity 
in disease is a vast area of investigation and is beyond the scope of this literature 
review. In recent years some investigation has been carried out into kinase activity in 
Behçet’s disease and the Suzuki groups have reported that excessive expression of Txk, 
a member of the Tec family of tyrosine kinases contributes to the excessive Th1 
cytokine production in BD (Nagafuchi et al., 2005). Other Kinases investigated have 
include Rho kinase (Oguz et al., 2012) and Gas6 (Gheita et al., 2012). While JAK2 and 
STAT3 polymorphisms have been reported in the Han Chinese population (Hu et al., 
2012). In this thesis the investigation of kinase activity has been focused on the Th1 and 




and the signalling molecules that might contribute to the overall pro-inflammatory 
profile which is the signature of the disease. 
1.10 Hypothesis 
Since increased production of pro-inflammatory cytokines are a key feature of BD, it is 
important to try to understand if this is a result of the response to pathogens or if it 
might be due to disregulation of the mechanisms that control the immune response.  
 Several cytokines implicated in BD such as IFNγ, IL-12, IL-23, IL-10 and IL-6 exerts 
their effects through activation of the JAK-STAT signalling pathways which are 
negatively regulated by SOCS proteins. In this respect, any dysregulation in this balance 
can affect cellular responsiveness to cytokines and cause subsequent pathological 
effects. At present there is limited data regarding expression of SOCS family in BD. 
Therefore this project was designed to investigate the expression of SOCS1-3 and to test 
the hypothesis that SOCS proteins are dysregulated in Behçet’s Disease.  
1.11 Aims 
Aims of this project were to: 
 Investigate expression of SOCS1 and SOCS3 in PBMCs, Neutrophils and 
Buccal mucosal cells of patients with BD. 
 Investigate Th1, Th2 and Th17 cytokines profile in BD. 
 Investigate expression of phosphorylation status of STAT1, STAT2, STAT3, 






























Chapter 2: Materials and Methods 
2.1 Ethics 
This project was carried out as part of the “Immunoregulation at the Mucosal Barrier 
Programme” and has ethical approval of the East London and the City Local Research 
Ethical Committee (LREC), Ref P/03/122 (Appendix 1). Healthy control samples were 
obtained from members of staff and the patient cohort was recruited from the outpatient 
departments at the Royal London Hospital, The Behcet’s Centre of Excellence (BCE) at 
the Bart’s and the London NHS Trust and St. Thomas’ Hospital with informed consent 
(Patient and Healthy Volunteer invitations Appendix 2 and 3, Consent forms Appendix 
4). Ethical approval was obtained for all sites. All samples were anonymised, coded and 
logged according to ethical guidelines. The samples were stored in a locked freezer at -
80⁰C and all patient data was entered onto a secure non-networked computer database 
that was password protected. 
 
2.2 Subjects 
Behçet’s Disease (BD) patients were diagnosed according to the International Study 
Group for Behçet’s Disease (Lancet 1990).  
Recurrent aphthous stomatitis (RAS) patients were used as disease controls and most of 
the ulcers in these volunteers were of the minor type. These were compared with 
healthy control volunteers (HC). The criteria for HCs were age 18 or older and self-
identified as healthy (Table 2.1). A small number of patients with oro-gential ulceration 
unrelated to BD were also recruited and used in limited studies (N=3). Demographic 




The demographics for the patients and controls used for each experiment are described 
in the relevant sections of the results Chapters 3, 4 and 5. 
Demographic and Clinical Features of the Investigated Patients and 
controls 
Study Period 2009-2013 n=119 





   Male 31.1 
   Female 69.9 
Race or Ethnicity 
  White British 23.5 
   Irish 3.4 
   Turkish 2.5 
   Bangladeshi 2.5 
   Other 9.2   Missing data for the rest 
Clinical Manifestations 
   Oral Ulcers 40.8 
   Genital Ulcers 13.3 
   Eye Lesions 10.7 
   Skin Lesions 25.3 
   Joint involvement 47.6 
   Encephalitis 12 
   Vascular involvement 3.4 
Relapse 23.6 
Treatment 
   Prednisolone 39.7 
   Azathioprine 38.1 
   CellCept* 4 
   Cyclosporin A 2.4 
   Colchicine 45.2 
   Aza+Colch+Pred 7.1 
   Pred+Aza 7.1 
   Pred+Colch 11.4 




Mean Age ±SD, years 37.27±11.8(19-61) 43.5±14.6(30-61) 
Female 60% 70% 
Male 40% 30% 
Table 3.1: Demographic and clinical features of the investigated patients and controls 
*CellCept is trade namefor Mycophenolic acid 





All the BD study population were examined for evidence of activity in the eyes, mouth, 
skin, joints, and were graded as being relapsed (BD-RE) or quiet (BD-Q).  
The patients were assessed in each clinic based on two questionnaires: clinical disease 
activity form (Appendix 5), patient perception of disease activity questionnaire 
(Appendix 6). 
 
BD patients were classified based on the overall disease activity, following a consultant-
led assessment, into the following categories: 
1) Relapsed (BD-RE): Severe disease activity in more than two of the BD 
symptoms despite treatment. 
2) Quiet (BD-Q): Disease activity in fewer than three of the BD symptoms 
2.3 Sample preparation 
Blood, Buccal Mucosal Brush Biopsies (BMBB) and saliva samples were collected 
from the 4 subject groups: For BD and RAS patient samples were collected during quiet 
and active/relapsed periods of disease. 
 
2.3.1 Blood Samples  
The un-clotted blood samples (EDTA tube) and clot activator tubes were transferred 
immediately to the Laboratory (for samples from London Royal Hospital and BCE) and 
within a few hours for samples from Guys and St Thomas’ Hospital. 
 
2.3.1.1 Separation of Peripheral Blood Mononuclear Cells (PBMCs) 
Peripheral blood mononuclear cells (PBMCs) and plasma were isolated from blood 
samples via density gradient centrifugation using Ficoll-Paque™ Plus according to the 




was diluted 1:1 with Dulbecco’s Phosphate Buffered Saline (PBS-Sigma-Aldrich 
Company Ltd, Dorset, UK) and layered on to FICOLL-PAQUE™ PLUS and 
centrifuged at room temperature for 35 minutes at 1700 rpm with brake off (in order to 
prevent disturbance of the gradient). The PBMCs appeared as a “fluffy” interface 
between the top layer (diluted plasma) and the lower layer (Ficoll). Red cells and 
Neutrophils sedimented through the Ficoll. The diluted plasma (1:2) was pipetted off 
into sterile containers, labelled and frozen at -80˚C until further use.  
 
Following two washing steps with PBS at 1200 rpm for 10 minutes with the brake on, 
the PBMCs were resuspended in RPMI 1640 containing 2mM vol/vol L-glutamine,, 200 
units/ml Penicillin and 200 units/ ml Streptomycin (Lonza, Slough, UK). Viable cells 
were enumerated using the Trypan Blue exclusion method according to the 
manufacturer's protocol (Sigm a Aldrich, UK). The cells were resuspended in 0.4% 
Trypan Blue and counted under low magnification using a haemocytometer. The cells 
were either resuspended at 25 x 10
6
 cells /ml and frozen in 10% dimethyl sulfoxide 
(DMSO-Sigma Aldrich, UK) in 90% v/v foetal calf serum (FCS: PAA Biologics) or 
immediately used in different assays. 
 
2.3.1.2 Serum 
Serum samples were separated from clot activator tubes by centrifuging at room 
temperature for 6 min at 3300 rpm, the supernatant was collected, aliquoted and stored 
at -80˚C until further use. 
 
2.3.1.3 Isolation of Neutrophils 
After isolation of PBMCs and plasma using Ficoll density-gradient centrifugation, the 




The pellet was resuspended in red blood cell (RBC) lysis buffer [8.26 g ammonium 
chloride (NH4Cl), 1 g potassium bicarbonate (KHCO3) and 0.037 g EDTA in 1 litre 
double distilled water (ddH2O), filter-sterilized] and incubated on ice for 10 minutes and 
then centrifuged at 500× g for 10 minutes. After two washing steps with 2% FCS in 
PBS at 1200 rpm for 10 minutes with the brake on ( in order to pellet the cells), the cells 
were counted and resuspended at required numbers in appropriate lysis buffer and 
stored at -80°C until further use. 
 
2.3.2 Saliva Samples  
Saliva was collected in 20ml universal tubes and centrifuged at 3500× g, 15minutes, at 
4 ˚C. The supernatant was aliquoted and frozen at -80 ˚C. 
 
2.3.3 Buccal mucosal brush biopsies (BMBB) 
The brush biopsies were taken from both ulcerated and non-ulcerated sites of oral 
mucosa of BD patients, RAS and HC. This procedure was carried out using 10 strokes 
of a nylon bristle cytology brush (Flow gene, UK) with 360° rotation from each side of 
buccal oral mucosa followed by dipping up and down in a 1.5ml eppendorf tube 
containing  500l RLT lysis buffer (QIAGEN Ltd, Manchester, UK) (Fedele, 2009). 




2.4.1 Western blot Analysis 
Western blotting was carried out to evaluate protein expression levels of SOCS1 and 3 




Neutrophils and PBMCs were extracted using a modification of the method described 
by Bussmeyer et al 2010. The cells were resuspended at 10
6
 /40µl in lysis buffer 
containing 20 mM HEPES [pH 7.9], 420 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% 
[vol/vol] Nonidet P-40, 20% [vol/vol] glycerol, 1 mM dithiothreitol, 1mM Na3VO4, 
50mM NaF, 1mM PMSF, 1µg/ml Aprotinin and 20% glycerol (all from Sigma-Aldrich, 
UK) and incubated on ice for 30 minutes. The NP-40 in this lysis buffer enables 
extraction of cytoplasmic, membrane-bound, or whole cell extracts. To obtain higher 
extraction yields, the lysate was disrupted using a Bioruptor sonicator (Diagenode, 
Cambridge, UK) on a medium intensity setting, pulsed for 10sec ON, 10 sec REST, for 
60 seconds in total. This step was followed by centrifugation at 12,000 g for 20 min at 
4°C. The supernatant was collected and the protein concentration was quantified using a 
colorimetric assay, BioRad DC (detergent compatible) Protein assay (Life science; 
Hertfordshire, UK) according to the manufacturer’s instructions. To perform the assay, 
5 dilutions of a Bovine Serum Albumin (BSA) standard protein from 0.2-3 mg/ml were 
made (Sigma Aldrich, UK). 5µl of standards and samples were added to a 96 well 
microtiter plate (Nunc, UK), 25 µl reagent A and 200 µl reagents B, respectively were 
added. After 15 minutes incubation at room temperature, the intensity of the colour was 
measured at 750nm on a spectrophotometric plate reader (Fluo Star OPTIMA; BMG 
Labtech, Germany). A standard curve was generated using a four parameter logistic (4-
PL) curve-fit (Microsoft Office Excel) for each set of samples assayed.  The protein 
concentrations of the samples under investigation were calculated using the standard 
curve. 
 
For Western blotting purpose, 15µg of Lysate was mixed with Nu PAGE 4 times 
concentrated (4x) sample buffer and 10 times concentrated (10x) reducing agent 




min at 95°C and separated on NuPAGE® Novex® 12% Bis-Tris Gels (1.0-mm thick, 
12-well) (Invitrogen, UK) at 120V for 90 minutes and transferred to a Polyvinylidene 
fluoride (PVDF) membrane (Immobilon; Sigma-Aldrich, UK) at 200 mA for 1hour at 
4°C. The membrane was blocked in a blocking buffer containing 5% wt/vol dried milk 
in 0.05% vol/vol Tween 20 in Tris-Buffered Saline (9 g Sodium chloride, 100 ml 1M 
Tris Base PH 7.5, diluted to 1000 ml with distilled water: TTBS) (Sigma-Aldrich, UK) 
for 1 hour at room temperature.  The membranes were then incubated overnight at 4°C 
in the presence of the following primary antibodies: 
 
0.5µg/ml Monoclonal mouse Antihuman SOCS-3 antibody (R&D Systems; Abingdon, 
UK), 1µg/ml Rabbit polyclonal Anti-SOCS1 antibody (Abcam3691, Cambridge, UK), 
specific for amino acids 199-211 of human SOCS 1, 1µg/ml Rabbit polyclonal Anti-
SOCS2 antibody (Abcam 92847, UK) specific for  the C-terminus of SOCS2 protein 
from Human and 0.5µg/ml was used. To assure equal sample loading mouse 
monoclonal anti GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) antibody 
(Abcam9484,UK) was chosen as loading control based on literature review and 
previous experiments in our department (Seoudi et al., 2013, Payvandi et al., 2004, Li et 
al., 2003). The membrane was washed three times for 10 minutes with TTBS, then 
probed with the secondary antibody at 1:1000 dilution of 10µg/ml stock solution of 
horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody or goat anti-
Rabbit IgG antibody (Thermo Scientific, Northumberland, UK).  
 
Following another 3, 10 minute washing steps, the protein bands were detected using a 
chemiluminescence system (Amersham ECL, GE Healthcare) according to the 




Detection Reagents for 4 minutes to produce chemiluminescent signals corresponding 
to the protein bands and then were developed on a radiographic film. 
 
To compare relative protein expression between samples, the pixel densities of each 
band were quantified by densitometry using a scanner (Epson Stylus SX100, UK) and 
Image J software (http://rsbweb.nih.gov/ij/index.html). To normalize the data, each 
target band was compared to the loading control and fold changes were calculated by 
dividing the value of the target proteins to the value of loading control x100 and their 
results divided by the value of positive control to compare samples in different gels.  
 
 2.4.2 The Enzyme-linked immunosorbent spot (ELISPOT) assay 
In order to enumerate Cytokine (IL-17, IL-6 and IL-23)-secreting cells in isolated 
PBMCs from HC, RAS, BD quiet and BD relapsed, ELISPOT analysis was performed. 
The following cytokine ELISPOT assay kits: Human Interleukin-23 (MABTECH, 
Sweden), ELISPOT Human IL-17 and IL-6 (R&D system; Abingdon, UK) were used 
according to the manufacturer’s instructions 
.  
To perform the assays  first the 96-well PVDF membrane ELISPOT plates (Millipore, 
Watford, UK) were treated with 15µl /well of 35% ethanol for 1min and washed twice 
with PBS. Using PVDF membrane treated with ethanol, resulted in a more efficient 
binding of capture antibodies and having a greater number and better quality of spots.  
The plate was then coated with 100 µl /well capture antibody diluted in filtered PBS and 
incubated overnight at 4°C. After removal of coating antibody and washing 3x with 
200ul/well PBS, the membrane was blocked with 200 µl /well complete Medium 
(RPMI-1640, 10%FCS, 1% Penicillin/Streptomycin/L-Glutamine) for 1 hour at 37° C. 






 cells/ml stimulated with 20µg /ml Human HSP70HEK 293( 
Human embryonic kidney) (supplied by Dr Britta Eis-Vespa, Hanover, Germany) and 
for polyclonal stimulus 5×10
5
 cells/ml stimulated with 50ng/ml 
LPS(Lipopolysaccharide) and 10µg/ml phytohaemagglutinin (PHA)( Sigma Aldrich, 
UK). Following aspiration of the blocking buffer, the cells were brought into wells in 
triplicate at 100µl/well. Unstimulated cells acted as a negative control and sterile culture 
media as a background control. Following incubation for 24 at 37°C, 5% CO2, they 
were emptied, washed with 0.05% Tween20 (Sigma Aldrich, UK) in PBS and probed 
with Biotinylated monoclonal antibody overnight at 4°C. To detect the spots two 
methods of spot development were compared: ELISPOT Blue colour Module (R&D 
SYSTEMS, UK) and the AEC (3-Amino-9-ethylcarbazole) coloured substrate system. 
In the ELISPOT Blue colour Module, the plates were incubated with Streptavidin–AP 
for 2 hours at room temperature. After incubation, the wells were washed 3 times with 
0.05% Tween20 in PBS and stained with 100 µl /well BCIP/NBT solution. Spots were 
visible after 20-30 minutes incubation in the dark at room temperature.  
 
In the AEC substrate system, the wells were incubated with Streptavidin-HRP (Sigma –
Aldrich) for 1hour at 37°C. After washing, a freshly prepared AEC substrate solution [1 
tablet of AEC in 2.5 ml of dimethylformamide (DMF) plus 47.5 ml of 50 mM acetate 
buffer (pH 5.0), 25 ml of fresh 30% (v/v) hydrogen peroxide] was added to develop the 
spots. The wells were rinsed with tap water to stop colour development and dried 
overnight. 
Spots were counted by use of an immunospot image analyser, Wallac Victor 1420 
multilabel counter (PerkinElmer, Cambridge, UK). All determinations were made in 
triplicate. The mean values calculated and the results presented as the number of 







2.4.3 Human Phospho-Kinase Array 
Expression of phosphorylated proteins in PBMCs was assessed by using the Proteome 
Profiler Human Phospho-Kinase Array kit (R&D Systems, Abingdon, United Kingdom) 
according to the manufacturer’s instructions. This pilot experiment was carried out on 
PBMCs from 3HC, 3 Active-minor-RAS, 3 BD-Quiet and 3 BD-Relapsed blood 
samples were separated using Ficoll density-gradient centrifugation. Isolated cells were 
resuspended in Lysis buffer 6, included in the kit at 1 × 10
7 
cells/mL and gently rocked 
for 30 minutes at 4°C. Then the cell suspension was centrifuged at 14,000 x g for 5 
minutes and the supernatant collected. The protein concentration of the supernatant was 
quantified using BioRad DC Protein assay (Life science, UK) according to the 
manufacturer’s instructions. All the samples were kept at -80 °C until further use. 
 
Each Human Phospho-Kinase Array kit contains eight nitrocellulose membranes in four 
pairs which capture and control antibodies of 46 kinase phosphorylation sites printed in 
duplicate on the membranes. Part A membranes contain 28 antibodies and part B 18 
antibodies. All the buffers and reagents were included in the kit. To perform the assay 
the nitrocellulose membranes were incubated in blocking buffer for 1 hour at room 
temperature. Samples were loaded, at 1mg/ml protein concentration, onto the 
membranes and incubated over night at 4°C. Following washing steps, the membranes 
was incubated first in specific detection buffers for 2 hours and then incubated in 
diluted Streptavidin-HRP for 30 minutes at room temperature on a rocking platform 
with 3 washing steps in between. Finally chemiluminescent detection reagents were 
applied to produce images following development on x-ray films, which detect signals 




Pixel densities of each spot were quantified by densitometry using scanner (Epson 
Stylus SX100, UK) and Image J software (http://rsbweb.nih.gov/ij/index.html). All the 
signal values were exported to a spread sheet file in Microsoft Excel. The average signal 
(pixel density) of the pair of duplicate spots for each phosphorylated kinase protein 
were calculated and subtracted from averaged background signal. To compare between 
different membranes, all the values on each membrane normalised to the Reference 
Spot value ×100 according to the manufacturer’s instructions. 
 
2.4.4 mRNA expression analyses 
The quality and quantity of the mRNA was evaluated throughout the study. 
 
2.4.4.1 Total RNA purification and quantification 
In order to investigate the mRNA expression of SOCS1-3 in PBMCs, Neutrophils and 
BMBB of BD patients in compare to HC and RAS, total RNA was extracted and 
reverse–transcribed to cDNA before proceeding to quantitative real time polymerase 
chain reaction (qPCR).  Total RNAs were isolated from the cells using RNeasy MiniKit 
(QIAGEN, Manchester, UK) according to the manufacturer’s instructions. Briefly 
5x10
6
 cells/ ml were lysed in RLT lysis buffer included in the kit and homogenized by 
vortexing for 5 minutes. In order to provide appropriate binding conditions, 1 volume of 
70% ethanol was added to the cell lysate and applied to the RNeasy Mini spin column. 
All the contaminants were washed away by three washing steps using buffer RPE and 
centrifugation steps.  Total RNA was eluted by addition of 30-50ul RNase-free water to 
the RNeasy spin column membrane. The concentration of RNA was determined by 






Finally to remove any contaminating DNA, all RNA preparations were treated by 
Ambion® TURBO DNA-free™ DNase kit (Applied Biosystems, Paisley, UK) 
according to the manufacturer’s instructions. The kit has been designed in addition to 
remove any contaminating DNA from RNA samples, inactivate DNase and remove any 
divalent cations from the sample. All the buffers and reagents were included in the kit. 
In a 50 µl Tubro DNase digestion, 5 ul of 10×TUBRO Buffer, 8 µl Nuclease-free H2O, 
1 µl TURBO DNase ( 2U /10µg RNA) were added  to 36 µl of RNA sample and loaded 
into the Veriti® Thermal Cycler (Applied Biosystems, UK) and run at 37°C for 
30minutes. After completing the run, 5 l of DNase Inactivation Reagent was added to 
each 50 l sample and incubated for 5 minutes at room temperature with occasional 
vortexing. After centrifuging at 10,000×g for 1.5 minutes, the clear supernatant was 
collected and stored in -80°C until further use. 
 
2.4.4.2 cDNA Generation 
Total RNA up to 2µg was reverse transcribed in a reaction volume of 20l using High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Paisley, UK) 
according to the manufacturer’s instructions. 10µl of 2× RT Master Mix contains 10× 
RT Buffer, 10× random primers, 25×dNTP mix (100Mm), MultiScribe™ Reverse 
Transcriptase, RNase Inhibitor and Nuclease-free H2O (all included in the kit) was 
added to 10µl of the total RNA and loaded into the Veriti® Thermal Cycler (Applied 
Biosystems, UK) and run at 25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 






2.4.4.3 Identification and validation of suitable endogenous reference genes 
In order to identify the most suitable reference genes for normalizing data in gene 
expression studies, geNorm kit (Primer Design, Southampton, UK) was used according 
to the manufacturer’s instructions. geNorm is a fast, established and standardized tool 
which is precisely designed and validated and has been used widely in many other 
studies (Etschmann et al., 2006). Six commonly used candidate reference genes (Table 




Gene Name Biological Process Cellular Component 
ACTB actin, beta 
involve in cell motility, 
structure, and integrity 
contractile apparatus and 






enzyme in catalyzing the sixth 
step of glycolysis 
 
UBC ubiquitin C 
Ubiquitination , 
protein degradation, 
DNA repair, cell cycle 
regulation, kinase 
modification, endocytosis, 






antigen processing and 
presentation of peptide 
antigen via MHC class I 
immune response 
Golgi membrane 
extracellular region plasma 
membrane early endosome 





mediate signal transduction 







protein synthesis component of the ribosome 





PBMC and 24 Neutrophil samples from the four study groups: HC, RAS, BD: Relapsed 
(RE) and Quiet (Q) by qPCR and the data were analysed using gNorm software 
(qbasePLUS) which was included in the kit. Using qbasePLUS permits fully automated 
calculations with easy and fast generation and interpretation of statistical results 
(Hellemans et al., 2007). 
2.4.4.4 Primer Design 
Specific cDNA sequences were obtained from the public GenBank sequence database 
of the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov), 
and primers were designed and ordered using Universal ProbeLibrary Assay Design 
Centre(RocheAppliedScience,http://www.rocheappliedscience.com/sis/rtpcr/upl/ezhom









SOCS1 5′- CCCCTGGTTGTTGTAGCAG -3′ 5′- GTAGGAGGTGCGAGTTCAGG-3′ 62 82 
SOCS2 5′- GGAGCTCGGTCAGACAGG -3′ 5′-GTTCCTTCTGGTGCCTCTTTT-3′ 84 79 
SOCS3 5′- AGACTTCGATTCGGGACCA -3′ 5′- AACTTGCTGTGGGTGACCA-3′ 128 93 
B2M 5′- TTCTGGCCTGGAGGCTATC -3′ 5′-TCAGGAAATTTGACTTTCCATTC-3′ 86 81 
GAPDH 5′-AGCCACATCGCTCAGACAC-3′ 5′- GCCCAATACGACCAAATCC -3′ 66 82 
ACTB 5′- CCAACCGCGAGAAGATGA-3′ 5′- CCAGAGGCGTACAGGGATAG-3′ 97 83 
UBC 5′-AGGCAAAGATCCAAGATAAGGA-3′ 5′-GGACCAAGTGCAGAGTGGAC -3′ 132 85 
Table 2.2: The gene sequences of primers used in RT-PCR. 
*The specific amplicon melting temperature (Tm) was determined by direct observation in its 
melting curve 
 
2.4.4.5 Reverse transcription polymerase chain reaction (RT-PCR)  
In order to perform amplification and detection of our target cDNA, real-time PCRs 




UK) using LightCycler 480 Sybr Green I Master mix (Roche Applied Science, UK) 
which contains Fast Start Taq DNA Polymerase and DNA double-strand-specific SYBR 
Green I dye for product detection and characterization. In 10 l reaction, 2l of cDNA 
was added to  5l of 2×Sybr Green I Master mix, 1ul of 5µM F/R primer and 3 l of 
dH2O and was run in a  PCR amplification starting with denaturation step (95°C for 
5min) followed by 45 cycles of amplification step (melting: 95°C for 10 seconds (s), 
primer annealing: 60°C for 6s and extension: 72°C for 6s) and finally melting analysis 
consists of melting (95°C for 30s), cooling/annealing (65°C for 30s), gradual heating 
with continuous acquisition (65°Cto 99°C) and cooling /termination (40 °C for 5s). 
Results were analysed with LightCycler® 480 Software, Version 1.5 (Roche Applied 
Science, UK) using Advanced Relative Quantification method. In this method, 
quantification was carried out using standard curves and the mean target gene 
expression values from duplicate samples were normalized by dividing them by the 
mean values obtained for house-keeping genes. 
 
2.4.4.6 Standard curve generation 
Performing a standard curve is necessary for absolute quantification of each gene. The 
mRNA gene copy number of an unknown sample was calculated based on the standard 
curve of that gene. Therefore, to  prepare the standard curve for each of our genes one 
of the PBMC samples was selected and incubated with 10µg/ml phycohaemagglutinin 
(PHA) for 3 days and then stimulated with human IFNγ for 1 hour. RNA was extracted 
and converted to cDNA (as described in 2.7.2, 3). A 50 µl normal PCR reaction 
contains 5ul of cDNA, 25ul of 2×Sybr Green I Master mix, 7ul of 5µM F/R primer and 





The PCR product purified using MinElute PCR Purification Kit (QIAGEN, Manchester, 
UK) according to the manufacturer’s instructions. The kit has been designed to perform 
a fast clean-up of up to 10 μg of DNA samples from enzymatic reactions which may 
interfere with subsequent downstream applications. 5 volumes (250μl) of Buffer PB 
were added to 1 volume (50 μl) of the PCR sample and mixed. To bind DNA, the 
sample was applied to the QIA-quick column and centrifuged for 1minute at 13,000 
rpm.  Buffer PB allows the efficient binding of single or double-stranded PCR products 
as small as 100 bp and the quantitative (99.5%) removal of primers up to 40 nucleotides 
to the silica membrane of QIAquick column. Any impurities such as salts and enzymes 
were washed away by adding 0.75 ml of ethanol-containing Buffer PE to the QIA-quick 
column and centrifuged for 1 minute. An additional centrifugation for 1min was carried 
out to remove any residual Buffer PE. To elute DNA, 20 μl Buffer EB (10 mM Tris·Cl, 
pH 8.5) was added to the centre of the membrane and the column was centrifuged for 1 
minute. The concentration of DNA was determined by measuring the absorbance at 
260nm using NanoDrop Nd-1000 Spectrophotometer. 
 
To generate a standard curve, the total number of DNA copies in the remaining 18 μl (2 
μl used for NanoDrop) was calculated based on the Avogadro’s Constant: 





 were made. The threshold cycle (CT values) were used to calculate and plot a linear 
regression line by plotting the logarithm of template concentration (X-axis) against the 
corresponding threshold cycle (Y-axis) using LightCycler® 480 quantification software, 





2.4.5 Cytokine secretion assays  
2.4.5.1 PBMC cell culture 
PBMCs from HC, BD relapsed (BD-R) and quiet (BD-Q) samples were separated using 
Ficoll density-gradient centrifugation (1700 rpm for 35min) as described in section 
2.3.1.1. After washing with PBS, isolated cells were resuspended in completed medium: 
RPMI 1640 (Lonza, UK) supplemented with 1% Penicillin/Streptomycin solution (P/S) 
and 10% Fetal Calf Serum (FCS), as previously described and incubated at a density of 
2×10
5
 /well.  The cells were stimulated with HSP70 (10 µg/ml), HSP27(200 µg/ml; 
Enzo Life Sciences, UK) and 10 µg/ml  phycohaemagglutinin (PHA: Sigma-Aldrich 
UK) incubated for 24 and 48 hours at 37°C, 5% CO2 and 100% humidity. Following 
incubation the non-adherent cells were collected and centrifuged at 800g for 10 minutes. 
The supernatant was collected and frozen for further cytokine assays. 
 
2.4.5.2 Multiplex cytokine quantification assay 
The levels of Th1/Th2 cytokines plus IL-17A in serum, saliva and cell culture 
supernatants from stimulated PBMCs were quantified in a multiplex bead array assay 
(MBAA) using Ready-to-Use FlowCytomix Multiplex (eBioscience, Bender 
MedSytems
®
, Ireland UK) according to the manufacturer’s instructions.  
 
Test procedure was performed using FACS tubes (Beckton-Dickenson, UK). Two series 
of standard curves in 1:7 serial dilutions from 0-10,000 pg/ml for IL-17A and IL-8 and 
0-20,000 pg/ml for the remaining cytokines were generated. To perform the assay first, 
25 μl of Standard Mixture dilutions 1 to 7, samples and assay buffer (as a negative 
control) were added to designated tubes. Then 25 μl of Bead Mixture and 50 μl of 
Biotin-Conjugate Mixture contain all cytokines in equal volumes  were added to all test 




shaker at 500 rpm. Biotin conjugated secondary antibody mixture bound to the analytes 
captured by the first antibodies coated by the beads. The tubes were washed 3 times 
with 1 ml of Assay Buffer and the beads were pelleted at 200 x g for 5 minutes. 50 μl of 
Streptavidin- Phycoerythrin (PE) Solution was added to all tubes and incubated at room 
temperature for 2 hours while protected from light with an aluminium foil. After 
another 3 washing steps, 500 μl assay buffer was added to each tube and samples were 
analysed on a flow cytometer. 
To collect data the beads were run on a FACS Calibur flow cytometer (BD FACS Canto 
II analyser). Further quantification and analysis of data from flow cytometer were 
performed using the FlowCytomix Pro 2.4 software (eBioscience, Bender MedSystems, 
UK). The minimum detectable concentrations using this kit was 1.6 pg/ml for IFN-γ, 
4.2 pg/ml for IL-1β, 16.4 pg/ml for IL-2, 20.8 pg/ml for IL-4, 1.6 pg/ml for IL-5, 1.6 
pg/ml for IL-6, 1.5 pg/ml for  IL-9, 1.2 pg/ml  for IL-10, 1.9 pg/ml for IL-12 p70, 1.5 
pg/ml for  IL-13, 4.5 pg/ml  for IL-17A, , 2.5 pg/ml for IL-22, and 43.3 pg/ml for TNF-
α . 
2.4.6 Phospho-specific flow cytometry 
Isolated PBMCs from HCs (n=7), BD-Q (n=8) and BD-RE (n=8) were investigated to 
measure the phosphorylation status of Signal transducer and activator of transcription 
proteins, STAT1, STAT2, STAT3, STAT5 and the transcription factors Tbet and 
RORt in subpopulations of PBMCs (CD4 Cells) following activation using a Phospho-
specific flow cytometry method (BD™ PhosphFlow, BD Biosciences). This method 
enables the simultaneous analysis of multiple intracellular phosphoprotein and cell 
surface markers in discrete subpopulations of cells. This was a pilot study on which a 
power calculation was not carried out. 
To perform the assay, the PBMCs were isolated using Ficol density gradient, 
resuspended at 10×10
6




stimulation-fixation and second permeabilization. In the first stage, 500µl (5×10
6
 cells) 
of cell suspension in a FACS tube were stimulated with 1.8×10
8
 units/mg Interferon-α 
(IFN-α) (PeproTech, London, UK) for 15min at 37°C using water bath. An 
unstimulated control sample of cells was set up in parallel. After stimulation, the cells 
were fixed immediately at equal volumes of 4% paraformaldehyde solution and 
incubated at 37°C for 10 minutes. Following incubation, fixed cells immediately were 
transferred to nunc cryovial tube and frozen at -80°C until further use.  
 
Intra cellular staining reagents 
Antibody Supplier 
Anti-Human/Mouse T-bet PerCPCy5.5 BD Biosciences (UK, Oxford) 
Alexa Fluor® 647 Mouse IgG1 κ Isotype 
Control 
BD Biosciences (UK, Oxford) 
PerCP-Cy™5.5 Mouse IgG2a κ Isotype Control BD Biosciences (UK, Oxford) 
Alexa Fluor® 647 Mouse IgG2a, κ Isotype 
Control 
BD Biosciences (UK, Oxford) 
PerCP-Cy™5.5 Mouse anti-Stat3 (pY705) BD Biosciences (UK, Oxford) 
Alexa Fluor® 647 Mouse Anti-Stat5 (pY694) BD Biosciences (UK, Oxford) 
Alexa Fluor® 647 Mouse Anti-Stat1 (pY701) BD Biosciences (UK, Oxford) 
Pacific Blue™ Mouse Anti-Human CD3 BD Biosciences (UK, Oxford) 
FITC-AntiCD4 Biolegend (London, UK) 
PerCP/Cy5.5 Mouse IgG1 κ Isotype Control Biolegend (London, UK) 
Table 2.3: Antibodies used for PhosphoFlow experiments  
 
In the second stage, the fixed cells were thawed at 37°C in a water bath, and 
immediately washed with FACS buffer (2% Fetal calf serum, 1 mM EDTA, 0.1% 




removed and 50 μl of residual volume was left. After disrupting the pellet by vortexing, 
the cells were permeabilized by adding 1ml permeabilization buffer (70% methanol pre 
chilled in -200C) vortexed again and incubated for 30minutes on ice. Then cells were 
washed 3 times by adding 3ml FACS buffer and centrifuging at 600g for 6 minutes. At 
the final wash, the cells were resuspended in FACS buffer at 10×106 cells /ml. To stain 
the cells, 100µl of cell suspension was added to all tubes with appropriate volume of 
antibody combinations (Table 2.3 and 2.4). 
 











































Table 2.4: Combination of BD PhosphoFlow antibodies.  
 
First 1 full drop (approximately 60 μl) of the BD™ CompBeads Negative Control 
(FBS) that have no binding capacity, and 1 drop of the BD™ CompBeads Anti-Mouse 
Ig, κ beads which binds light chain-bearing immunoglobulin as a positive control to 




(background fluorescence) stained populations to optimize fluorescence compensation 
settings for multicolour flow cytometric analyses. 
In order to confirm the specificity of primary antibody binding and to rule out non-
specific Fc receptor binding or other cellular protein interactions, isotype control 
antibodies in parallel with target antibodies were used. After adding the appropriate 
antibodies, the mixture was incubated for 60 minutes while protected from the light. 
Following another washing step, cells were resuspended in 500l of FACS buffer prior 
to flow cytometric analysis (BD FACS Canto II analyser Flow cytometry). 
 
2.5 Statistical analysis 
GraphPad StatMate 2 software was used to evaluate sample size and power. (GraphPad 
Software, Inc. USA). The Statistical analysis was performed using GraphPad Prism 5 
GraphPad Software, Inc. USA). Analyses of variance (ANOVA), non-parametric 






































Chapter 3: SOCS Expression  
In order to identify the factors that may cause dysregulation of cytokines in BD, PBMC 
and neutrophils were subjected to analysis of SOCS1-3 mRNA and protein expression 
using RT-PCR and western blot respectively. The mRNA expression of SOCS1 and 3 in 
buccal mucosal brush biopsies (BMBB) were also investigated. 
3.1 mRNA expressions of SOCS1-3 in BD 
3.1.1 Identification and validation of suitable endogenous reference genes  
In order to verify the most suitable reference genes for normalizing data in gene 
expression studies, 6 possible candidates: ACTB, GAPDH, UBC, B2M, YWHAZ and 
18S rRNA were selected for examination following a literature review (Zhang et al., 
2005, Stamova et al., 2009). 
 
The expression level of these genes was measured in 24 PBMC and 24 Neutrophil 
samples from 4 study groups: HC, RAS, and BD: Relapsed (RE) and Quiet (Q) by 
qPCR and the data were analysed using qbasePLUS software (Primer Design, 
Southampton, UK). The results showed the average expression stability value (M) of 
reference genes at each step during stepwise exclusion of the least stably expressed 
reference (Appendix 7). The least stable gene is located at the left and in this respect 
they were ranked based on increasing expression stability; therefore the most stable 
genes are seen on the right. The gNorm analysis showed that B2M, BACT and UBC in 
neutrophils and B2M, BACT and GAPDH in PBMCs are the most stably expressed 
genes for normalization in our study on Behçet’s disease. For buccal mucosal cells 
GAPDH was determined to be the most appropriate based on previous experiments in 




3.1.2 mRNA expressions of SOCS1-3 in PBMCs & Neutrophils  
The mRNA expressions of SOCS1-3 were quantified in 54 PBMCs and neutrophil   
samples including BD-All (n=28), BD-Q(n=18), BD-RE(n=10), HC (n=16), and RAS 
(n=10). The demographic and clinical features of the study groups are presented in 
Table 3.1. Of the 28 investigated BD patients, 7 were male and 21 were female.  
Demographic and Clinical Features of the Investigated Patients(n=28) 
Mean Age ±SD, years 37.27±11.8(19-61) 
Gender n       n % 
Male 7 25 
Female 21 75 
Clinical Features 
Oral Ulcers 16 57.1 
Genital Ulcers 4 14.3 
Eye Lesions 1 3.6 
Skin Lesions 9 32.1 
Joint involvement 12 42.9 
Encephalitis 2 7.9 
Vascular involvement 2 7.9 
CNS 3 10.7 
Relapse d                                
 10 
10 35.7           
Treatment 
Prednisolone 5 17.9 
Azathioprine 8 28.6 
CellCept 1 3.6 





Mean Age ±SD, years 37.27±11.8(19-61) 43.5±14.6(30-61) 
Male 8(50%) 3(30%) 
Female 8(50%) 7(70%) 





The most frequent clinical symptoms were oral ulcers (57.1%), joint involvement 
(42.9%), and skin lesions (32.1%). From the disease activity view point, 10 patients 
(35.7%) were clinically diagnosed as fully relapsed (i.e. activity in 3 or more systems). 
Treatment information of 16 patients was available (Table 3.1) and 3 patients were not 
on any immunosuppressant medication at the time of sample collection. The data on 
relative mRNA expression from BD patients were compared with HC and RAS and also 
with disease activity in BD: quiet and relapsed, using ANOVA and the Mann–Whitney 
U-test  
 
3.1.3 SOCS1 is upregulated in PBMCs from BD patients 
The mRNA expression levels of SOCS1in PBMCs and neutrophils were shown to 
exhibit a different pattern in BD patients compared to HC. As can be seen from Figure 
3.1, SOCS1 expression has increased in both PBMC and neutrophils in BD patients 
compared to healthy controls. This difference was not significant in neutrophils 
(ANOVA: P=0.9353; Figure 3.1a) despite the mean level in HC being lower than that of 
BD-Q and the combined values of all BD (HC= 0.4272 compared with BD-Q = 0.6127 
and All BD = 0.1709). However, PBMC displayed a significant difference between 
study groups (ANOVA: P=0.0274; Figure 3.1b). The SOCS1 level in BD patients was 
higher than both HC and RAS, p=0.0149 and p=0.0325 respectively, in PBMC. 
Moreover, both the quiet and relapsed subgroups showed significantly higher levels of 
SOCS1 at p=0.0343 and p=0.0427 respectively (Figure 3.1b). No significant differences 
were found between quiet and relapsed patients. Comparison of RAS with both BD-RE 
and BD-Q patients just failed to reach significance and was probably a reflection of the 




































































































Figure 3.1: SOCS1 expressions in PBMCs and neutrophils. mRNA expressions of SOCS1 were 
quantified by RT-PCR and the results were normalized against the expression levels of B2M, 
BACT and GAPDH. The mean mRNA relative expressions of SOCS1 were compared between 
HC, RAS, and BD patients with relapsed or quiet BD using one-way ANOVA and Mann–
Whitney U-test. Bars represent mean values ± SEM. * P<0.05 
 
3.1.4 SOCS 3 is highly expressed in the Neutrophils of quiet BD 
The expression of SOCS 3 mRNA showed significant upregulation in both PBMCs and 
Neutrophils. As can be seen, both display marked differences in SOCS3 expression 
(Figure 3.2a; ANOVA: P=0.0024 and Figure 3.2b; P=0.0031). The most striking result 
to emerge from this graph is the very high level of expression in BD-Q. From the scale 
of the y axis it can be observed that there is about a 10 fold difference in expression in 
Neutrophils compared to PBMCs. There is significant upregulation of both PBMC and 
neutrophil SOCS3 when all BD patients are grouped together and compared to HC at 
p=0.0007 and p=0.0015 respectively. In addition, both PBMC and neutrophils 
demonstrated increased expression of SOCS3 in RAS in comparison with HC at 
p=0.0307 p=0.0149. There was no significant difference within BD subgroups, relapsed 
and quiet. From the data in Figure 3.2a, it is apparent that in neutrophils both quiet and 
relapsed patients display marked higher expression of SOCS3 compared to HCs at 




PBMCs at p=0.0066 and p=0.0055 respectively (Figure 3.2b). However unlike SOCS1, 
the ratio of quiet to relapsed SOCS3 level in neutrophils and PBMCs is reversed. While 
in neutrophils, the mean levels of SOCS3 (1.385±0.1914) in quiet patients were higher 
than relapsed (0.4099±0.0422), in PBMCs the mean level of relapsed 







































































































 Figure 3.2: SOCS3 expressions in PBMCs and neutrophils.  mRNA expressions of SOCS3 
were quantified by RT-PCR and the results were normalized against the expression levels of 
B2M, BACT and GAPDH. The mean mRNA relative expressions of SOCS3 were compared 
between HC, RAS, and BD patients with relapsed or quiet BD using one-way ANOVA and 
Mann–Whitney U-test. Bars represent mean values ± SEM. * P<0.05, ** P<0.01, ***P<0.001.  
 
3.1.5 SOCS2 is upregulated in the PBMCs of relapsed BD 
SOCS2 expression showed significant differences between HC and the BD subgroups in 
Neutrophils (Figure 3.3a; ANOVA P=0.946). Similarly, as can be seen from Figure 
3.3b, BD relapsed patients display a higher mean level of SOCS2 mRNA expression in 
PBMCs than HC, but this just fails to reach significance (Mann-Whitney; p=0.0587), 
despite an unpaired t test giving a significant difference of p= 0.0166 and F test for 




(p=0.0133). The means levels of SOCS expression in BD-Q and RE were somewhat 
different with BD-RE having the higher levels but the comparison did not reach 
significance (p= 0.0616). Since SOCS2 is thought to have a somewhat different 



























































































Figure 3.3: SOCS2 expressions in PBMCs and neutrophils. mRNA expressions of SOCS2 were 
quantified by RT-PCR and the results were normalized against the expression levels of B2M, 
BACT and GAPDH. The mean mRNA relative expressions of SOCS2 were compared between 
HC, RAS, and BD patients with relapsed or quiet BD using one-way ANOVA and Mann–
Whitney U-test. Bars represent mean values ± SEM. *p<0.05 
 
3.2 Western blot analysis of SOCS3 and SOCS1 in Neutrophils and 
PBMC 
In order to investigate post transcriptional regulation of SOCS, the protein expression of 
SOCS1 and 3 was analysed in  PBMC and neutrophil samples in BD (n=22) and HC 
(n=11 PBMCs, n=7 Neutrophils) using the western blot method. The demographic and 
clinical features of investigated BD patients are presented in Table 3.2.  





Demographic and Clinical Features of the Investigated Patients (n=22) 
Mean Age ±SD 40.68±15.3 
Gender n  % 
Male 8 36.4 
Female 14 63.6 
Clinical Features 
Oral Ulcers 9 40.9 
Genital Ulcers 1 4.5 
Eye Lesions 2 9.1 
Skin Lesions 5 22.7 
Joint involvement 17 77.3 
Encephalitis   
Vascular involvement 1 4.5 
Gastrointestinal 1 4.5 
Relapsed 4 18.2 
Treatment 
Prednisolone 7 31.8 
Azathioprine 9 40.9 
Colchicine 6 27.3 
Table 3.2: Demographic and Clinical characteristics of investigated patient in protein 
expression experiments. 
 
clinical symptoms were joint involvement (77.3%), oral ulcers (40.9%), CNS (27.3%) 
and skin lesions with 22.7%. 4 patients (18.2%) were clinically diagnosed as relapsed. 
The data on SOCS1 and SOCS3 relative pixel density of BD patients were compared 
with those of  HCs and also with disease activity: quiet and relapsed using ANOVA and 
Mann–Whitney U-test (Figures 3.4 and 3.5). SOCS2 was  not abundantly present in all 
samples since was it difficult to detect by western blot in unstimulated samples. SOCS2 




the experiments was on SOCS1 and 3. SOCS1 and SOCS3 bands were detected around 
30kDa (Figure 3.4c and 3.5c). 
SOCS1 and 3 protein expression results in PBMCs were summarized in Figure 3.4. 
While for SOCS3, strong bands were detected, SOCS1 bands were faint in most of 
samples (Figure 3.4c). As can be observed from Figure 3.6a, SOCS1 protein expression 
in PBMC did not display any significant difference between investigated groups 





































































Figure 3.4: SOCS1 and SOCS3 protein expressions in PBMCs. Relative protein expression of 
SOCS1 and 3 were quantified by western blot. The results were normalized against GAPDH as 
a loading control and between membranes by a positive control. The mean relative pixel density 
of SOCS1 and SOCS3 were compared between HC and BD patients with relapsed or quiet BD 
using one-way ANOVA and Mann–Whitney U-test. Bars represent mean values ± SEM of HC 





100% increase in BD quiet and  a 50% reduction in BD-RE when they were compared 
with HCs but these differences were not significant (p=0.743 and p=0.4278 
respectively). No noticeable difference between investigated groups was seen in SOCS3 
protein expression by PBMCs (Figure 3.4b; ANOVA P=0.9481). 
 
SOCS1 protein is highest in the Neutrophils of relapsed BD 
The protein expression level of SOCS1 in neutrophils was shown to express a markedly 
different pattern in BD patients compared to HC (ANOVA, P=0.0308). As can be seen 
from Figure 3.5a, SOCS1 protein expression was increased significantly in BD relapsed 
compared to HCs at (p=0.0317) in neutrophils. The most striking observation from the 
graphs in Figure 3.5 is the significant difference between BD relapsed and quiet of both 
SOCS1 and SOCS3 but in slightly different ways. While SOCS1 is upregulated in 
relapsed compared to quiet (p=0.0338), SOCS3 has shown a significant reduction in 
relapsed compared to quiet at p=0.0393. There was no difference in SOCS 3 protein 
expression, between HCs when compared to BD in neutrophils. Overall, the expression 
of SOCS1 and 3 has increased in BD patient compared to healthy controls both in 
messenger and protein level; however, there were some differences in the ratio of quiet 













































































Figure 3.5: SOCS1 and 3 protein expression in neutrophils. Relative protein expression of 
SOCS1 and 3 were quantified by western blot. The results were normalized against GAPDH as 
a loading control and between membranes by positive control. The mean relative pixel density 
of SOCS1 and SOCS3 were compared between HC and BD patients with relapsed or quiet BD 
using one-way ANOVA and Mann–Whitney U-test (a and b). Bars represent mean values ± 
SEM of HC (n=.5), BD-Q (n=12), RE (n=4) for SOCS1 (a) and HC (n=.7), BD-Q (n=13), RE 
(n=6) for SOCS3(c). * p<0.05 
3.3 mRNA expressions of SOCS1-3 in Buccal Mucosal Cells (BMC) 
Considering the importance of oral ulcers in Behcet’s disease, SOCS1 and 3 expressions 
were investigated in buccal mucosal cells (BMC). The samples were taken from ulcer 
and non-ulcer sites of buccal oral mucosa by brush biopsy (BMBB: Chapter 2 section 
2). The mRNA expressions of SOCS1 and 3 were quantified in 34 BMC samples 
including BD (n=17 pairs of matched ulcer and non-ulcer samples) and HC (n=17). The 




Demographic and Clinical Features of the Investigated Patients(n=17) 
Mean Age ±SD 35(25-57) 
Gender n  % 
Male 5 33.3 
Female 10 66.7 
Clinical Features 
Oral Ulcers 17 100 
Genital Ulcers 3 18.8 
Eye Lesions 1 6.3 
Skin Lesions 3 18.8 
Joint involvement 12 75 
Encephalitis 2 12.5 
CNS 5 31.3 
Relapsed 7 41.2 
Treatment 
Prednisolone 2 12.5 
Azathioprine 3 18.8 
CELLCEPT 1 6.3 
Colchicine 7 41.2 
 Table 3.3: Demographic and Clinical characteristics of investigated patients with Behcet’s 
disease. 
 
Of the 17 investigated BD patients, 66.7% female and 33.3% were male. All the 
patients were selected based on having active oral ulcers. Around 41% were diagnosed 
as fully relapsed. The most frequent clinical symptoms after oral ulcers were joint 
(75%), and CNS (31.3%) involvements. The treatment information of 15 patients was 
available and one patient did not have any medication. Half of the patients were 
prescribed colchicine alone or in combination with prednisolone or azathioprine. The 




areas and HCs also comparing BD disease activity: quiet and relapsed using ANOVA 
and Mann–Whitney U-test. 
 
SOCS 1 and 3 are increased in ulcerated mucosa 
The mRNA expression levels of SOCS1 and SOCS3 in matched ulcer and non-ulcer 
sites of BD patients and buccal mucosal cells from healthy controls  display very 
significant differences (Figure 3.6a: ANOVA, P=0.0001; Figure 3.6b: ANOVA, 
P=0.0001). As shown in Figure 3.6a, SOCS1 has increased significantly in ulcer sites 
compared to non-ulcer sites and also compared to non-ulcerated  healthy controls 
(p=0.0114 and p=0.0001 respectively). Although, the mean expression level of SOCS1 
in non-ulcer sites (0.2243±0.08457) was higher than HCs (0.05750±0.01147) it failed to 
reach significance (p=0.4282). Similarly, SOCS3 expression followed the same pattern 
as SOCS1. As can be seen from Figure 3.6b, SOCS3 has also increased significantly in 
ulcer sites compared to non-ulcer sites and healthy control samples (p= 0.0004 and 
p=0.0001 respectively).  The mean expression level of SOCS3 in non-ulcer sites 
(0.08460±0.05601) were higher than HCs (0.0215±0.007025) but similar to SOCS3, it 











































































Figure 3.6: SOCS1 and SOCS3 expressions in buccal mucosal cells from brush biopsies.  
mRNA expressions of  SOCS1 and SOCS3 were quantified by RT-PCR and the results were 
normalized against the expression levels of GAPDH. The mean mRNA relative expressions of 
SOCS1 and 3 were compared between HC, Ulcers (U) and Non-Ulcer (NU) sites of BD patients 
using one-way ANOVA and Mann–Whitney U-test. Bars represent mean values ± SEM. * 
P<0.05, ** P<0.01, ***P<0.001.  
 
Further analysis of SOCS1 and 3 expressions in BMC, comparing quiet and relapsed 
patients is presented in Figure 3.7. As can be seen from Figure 3.7a and 3.7b, as 
predictable, there are no noticeable differences in  both SOCS1 and 3 in non-ulcer sites 
comparing relapsed with quiet patients (p=0.4396, p= 0.4634 respectively), although the 
errors are large. There is a significant upregulation of SOCS3 in HCs in comparison to 
non-ulcer sites of quiet patients (Figure 3.7b: p=0.042).  Conversely, in ulcer sites, the 
relapsed patients displays higher relative mean expression of SOCS1 (0.5876±0.2597) 
than in quiet pa  
tients (0.2452± 0.506). In the same way, SOCS3 was higher in relapsed patients (1.433± 
1.004) than in quiet BD (0.36± 0.101; Figure 3.7d) but both failed to reach significance. 
However, both relapsed and quiet patients display very significant increase of both 
SOCS1 and SOCS3 in ulcer sites compared to HCs (Figures3.7c and 3.7d). In ulcer sites 




p=0.0063 respectively (Figure3.7C). Similarly, SOCS3 presents the same trend at   
































































































































































Figure 3.7: SOCS1 and SOCS3 expressions in buccal mucosal cells from brush biopsies.  
mRNA expressions of  SOCS1 and SOCS3 were quantified by RT-PCR and the results were 
normalized against the expression levels of GAPDH. The mean mRNA relative expressions of 
SOCS1 and 3 in relapsed patient were compared to quiet ones in non-ulcer sites(a and b) and 
ulcer sites(c and d) using one-way ANOVA and Mann–Whitney U-test. Bars represent mean 
values ± SEM. * P<0.05, ** P<0.01, ***P<0.001 
 
BD patients frequently present with only oral ulceration and in this respect are regarded 




interesting differences. Figure 3.8 demonstrates further analysis of SOCS1 and 3, 
comparing ulcer and non-ulcer sites in which relapsed and quiet patients were distinctly 
different. As can be seen, there is a significant upregulation of SOCS1 and SOCS3 in 
ulcer sites of quiet patients compared to their non-ulcer sites at p=0.0117 and p=0.0031 
respectively (Figure 3.8a and 3.8b). Regarding relapsed patients, SOCS3 was also 
significantly increased in ulcer sites compared to non-ulcer sites at p=0.177(Figure 
3.8d). The mean level of relative expression of SOCS1 in ulcer sites (0.5876±0.259) 
was higher than non-ulcer sites (0.2035±0.156) but it failed to reach significance 
(p=0.202; Figure3.8C). 
  
The relative expression of both SOCS 1and SOCS3 is much higher in the relapsed 
patients compared with the “quiet” patients and there was also a striking difference 
between ulcer and non-ulcer sites. This might suggest that the local environment is 
critical for SOCS expression and might further suggest that the expression in the 
Neutrophils and lymphoid compartment may not reflect activity in the mucosal tissue. 
Conversely, the activity in the local mucosal tissue might be dependent on the type of 
cell infiltrating the mucosa and whether these cells arrive with their SOCS proteins up-
or down regulated or are dependent on the signals from the local environment to 








































































































































































Figure 3.8: SOCS1 and SOCS3 expressions in buccal mucosal cells from brush biopsies.  
mRNA expressions of  SOCS1 and SOCS3 were quantified by RT-PCR and the results were 
normalized against the expression levels of GAPDH. The mean mRNA relative expressions of 
SOCS1 and 3 in non-ulcer sites and ulcer sites were compared in quiet (a and b) and relapsed(c 
and d) patients using one-way ANOVA and Mann–Whitney U-test. Bars represent mean values 
































Chapter 4: Cytokine profile in a UK cohort of BD patients 
4.1 Serum and saliva cytokine profiles in Behçet’s disease 
Cytokines are thought to contribute to the pathogenesis of BD and their levels in the 
serum or saliva might provide diagnostic or activity markers for the disease. Therefore 
the levels of 12 cytokines representative of the Th1, Th2 and the Th17 pathways were 
quantified in a multiplex bead analysis detection system as described in Chapter 2 
section 2. Serum and saliva of patients with BD are compared with healthy controls 
(HC), recurrent aphthous stomatitis (RAS) and patients with Oro-Genital Ulceration 
(OGU). 
 
4.1.1 Serum cytokine profile 
The 12 cytokines were quantified in 79 serum samples including BD (n=58), HC 
(n=12), OGU (n=3) and RAS (n=6). Of the 58 investigated BD patients, 15 were male 
and 43 female. The most frequent clinical symptoms were oral ulcers (40.7%), joint 
disease (32.2%) and skin lesions (20.3%). From the disease activity viewpoint, 16 
patients (27.1%) were considered as fully relapsed. Treatment information of 47 
patients was available (Table 4.1). The data on the levels of detectable cytokines from 
BD patients were compared with HC, OGU, and RAS and also with disease activity in 
BD (quiet and relapsed) using ANOVA and Mann–Whitney U-test (Figures 4.1 and 
4.2).  
As can be summarised from Table 4.2, the most abundant cytokines in the serum of BD 
patients were IL-8 (detected in 56 out of 58 patient sample), TNF-α (39 /58), IL-1β (23 
/58) and IL-4(21/58) respectively. IL-6 was undetectable (only 2 out of 79), also IL-5 




Demographic and Clinical Features of the Investigated Patients (n=58) 
Mean Age ±SD, years 42.34±12.6 (22-78) 
Gender  n                  % 
Male 15 25.4 
Female 43 74.6 
Clinical Features 
Oral Ulcers 24  40.7 
Genital Ulcers 9 15.3 
Eye Lesions 5 8.5 
Skin Lesions 12 20.3 
Joint involvement 19 32.2 
Encephalitis 3 5.1 
Vascular involvement 3 5.1 
Relapsed* 16 27.1 
Treatment 
Prednisolone 4 6.8 
Cyclosporin A 1 1.7 
CellCept 1 1.7 
Colchicine 11 18.6 
Azathioprine 7 11.9 
Aza+Colch 9 15.3 
Pred+Colch 3 5.1 
Cyc+Col 1 1.7 
Aza+Cyc 2 3.4 
Pred+Aza 5 8.5 
Pre+Aza+Col 2 3.4 
Table 4.1: Demographic characteristics, clinical features and immunosuppressive drug 
treatment of investigated BD patients at the time of serum collection. * Where relapsed is 
defined as disease activity in at least 3 tissues: See Chapter 2 section 2. 
 
TNF-α and IL-1β were raised in BD patients compared to HC but the differences were 
not statistically significant. The results revealed that mean serum level of relapsed cases 
were higher than quiet cases for IL-12p70 (12.54 vs 7.3pg/ml) and IL-10 (5.7 vs 
3.4pg/ml) but lower than quiet for IL-17A (6.1 vs 14.9pg/ml), IL-2 (8.4 vs 22.4pg/ml) 
and IL-8 (140 vs 1659pg/ml) . However the differences did not reach statistical 




undetectable values in the method the data were re-analysed comparing those samples 
which gave positive results (Table 4.2 and Fig 4.3). However, no significant differences 
were observed and it was concluded that the very large range of values obtained from 
both the patients and the controls made comparisons very difficult. This has been 
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Figure 4.1: Serum levels of IL-12p70, IFN-γ, IL-17A, IL-2, IL-10 and IL-8 were measured by 
multiplex bead analysis. The mean concentration (pg/ml) of each individual cytokine were 
compared between HC, RAS, OGU and BD patients with Relapsed or quiet BD using one-way 
ANOVA and Mann–Whitney U-test. Horizontal lines represent the mean cytokine levels 
(pg/ml) in each group. There was no significant difference between study groups except for IL-8 












































































































































































































Figure 4.2: Serum cytokine levels (pg/ml) of IL-4, IL-β, IL-5, TNFα, TNF- β and IL-6 were 
measured by multiplex bead analysis. The mean concentration (pg/ml) of each individual 
cytokine were compared between HC, RAS, OGU and BD patients with Relapsed or quiet BD 
using one-way ANOVA and Mann–Whitney U-test. There was no significant difference 



































































































































































































Figure 4.3: Detectable serum levels of IL-4, IL-2, IL-8, IFN-γ IL-β and TNFα, (pg/ml).The 
mean concentration (pg/ml) of each individual cytokine were compared between HC, RAS, 
OGU and BD patients with Relapsed or quiet BD using one-way ANOVA and Mann–Whitney 
U-test. Bars represent mean values ± SEM.  
 
In order to evaluate whether the immunosuppressive medication course prescribed to 
BD patients affected their cytokine profile, the serum levels of IL-8 and TNF-α, which 




divided into different groups according to drug treatment: BD patients with only 
Prednisolone or Colchicine (Pred or Col), BD patients with Prednisolone or Colchicine 
in combination with other immunosuppressant drugs (Pred+ or Col+)  (Figure 4.4). 
Unfortunately, due to the nature of presentation at our clinics, hardly any patients could 
be found who were not already taking medication when entering the study. The results 
showed no significant differences; therefore Prednisolone or Colchicine did not appear 
























































































Figure 4.4: Serum levels of IL-8 and TNF-α (pg/ml) in BD patients with prednisolone alone 




immunosuppressant drug (Pred+ n=9, Col+ n=15) and any other treatments (other, n=7) at the 
time of sample collection. Bars represent mean values ± SEM in each study group. 
 
4.1.2 Matched Serum and Saliva cytokine profile  
The levels of the 12 cytokines were also quantified in 37 matched serum and saliva 
samples from HC (n=10), RAS (n=7), BD (n=20) using a multiplex bead analysis 
detection system (Table 4.3). 
Demographic and Clinical Features of the Investigated Patients(n=20) 
Mean Age ±SD, years 37.30±9.25 (22-53) 
Gender N  %                n 
Male 6 30 
Female 14 70 
Clinical Features 
Oral Ulcers 9 45 
Genital Ulcers 4 20 
Eye Lesions 3 15 
Skin Lesions 3 15 
Joint involvement 10 50 
Encephalitis 2 10 
Vascular involvement 1 5 
CNS 2 10 
Relapsed 13 65 
Treatment 
Prednisolone 7 35 
Pred+ 3 15 
Colchicine 4 20 
Azathioprine 3 15 
No Treatment 2 10 
Table 4.3: Demographic characteristics, clinical features and immunosuppressive drug 




Of the 20 BD patients investigated 30% were male and 70% were female. The most 
frequent clinical symptoms were joint involvement (50%) oral ulcers (45%) and genital 
ulcers (20%) (Table 4.3) 65% of patients were considered as fully relapsed. The mean 
cytokine levels (pg/ml) from BD patients in either relapsed or quiet phases of disease 
were compared with HC and RAS using ANOVA and Mann–Whitney U-test. BD 
groups were further subdivided into those patients with active oral ulcers compared with 
orally quiet patients. 
 
The most abundant cytokines in the serum of BD patients were IL-8(detected in 17 out 
of 20 BD samples), IL-2 (11/20), TNF- α (10/20) and IL-10(10/20). Interestingly, 
cytokines seemed to be more abundant in the saliva, with 17 out of 20 samples 
containing IL-8, IL-10, IL-1β and TNF-β. 
 
The results, as shown in Figures 4.5,-4.8 suggest that the salivary proinflammatory 
cytokine profile is quite different from serum. Very little IL-1β was detected in HC or 
RAS serum and only 5 out of 20 BD patients had  measurable levels. However, it was 
interesting to note that the range in serum and saliva were very different. Maximum 
values obtained in a serum sample from a BD-Q sample was 399.0pg/ml, whereas in 
saliva the range for all groups was up to 4000.0pg/ml with one HC sample lying outside 
the axis range (not shown) at >8000.0pg/ml. Similarly IL-6 was not detected in serum 
(except for one BD-Q patient; Fig 4.5) but was detected in all groups of saliva but at a 
maximum of 724pg/ml in one BD-relapsed sample. TNF-α and IL-6 were higher in BD 
patients compared to HCs but only IL-6 reached significant increase in BD-RE 
compared with HC at p=0.0283. Further statistical analysis revealed that IL-6 had 
increased significantly in patients with oral ulcers compared to HCs regardless of 




relapsed BD versus quiet BD (p=0.0079). Il-6 was higher in the saliva of patients with 
ulcers than without (p=0.0269). TNF-α levels were higher in BD relapsed and patients 
with oral ulcers compared with HCs but these just failed to reach significance 
(p=0.0586 and p=0.0602 respectively).  
 
Serum and saliva cytokine levels of Th1 cytokines IL-12P70, IFN-γ and IL-2 did not 
reach any significant differences among the study groups (Figure 4.6). Saliva IFN-γ was 
detected in only 13 out of 37 samples and was the least abundant cytokine in saliva. 
From the data in Figure 4.7, it is apparent that Th2 cytokines IL-4 and IL-5 were 
detected only in very few serum samples and in saliva no significant differences were 
found between investigated groups. 
 
The results obtained for IL-17A, IL-8 and TNF-β are presented in Figure 4.8. As can be 
seen, while IL-17A and TNF-β were detected only in a few of BD serum samples, they 
were quite abundant in BD saliva samples; however, there were no significant 
differences between investigated groups. IL-8 was plentiful in both serum and saliva 





































































































































































































Figure 4.5: Comparison between serum and saliva cytokine levels (pg/ml) of IL-β, TNFα, and 
IL-6 in investigated groups:  HC, RAS, BD patients in relapsed or quiet state and BD with oral 










































































































































































































Matched Serum& Saliva Cytokine Profile in BD
 
Figure 4.6: Comparison between serum and saliva cytokine levels (pg/ml) of IL-12p70, IFNγ, 
and IL-2 in investigated groups:  HC, RAS, BD patients in relapsed or quiet state and BD with 





































































































































































































Matched Serum& Saliva Cytokine Profile in BD
 
Figure 4.7: Comparison between serum and saliva cytokine levels (pg/ml) of IL-4, IL-5, and 
IL-10 in investigated groups:  HC, RAS, BD patients in relapsed or quiet state and BD with oral 








































































































































































































Matched Serum& Saliva Cytokine Profile in BD
Figure 4.8: Comparison between serum and saliva cytokine levels (pg/ml) of IL-17, IL-8 and 
TNF-β in investigated groups:  HC, RAS, BD patients in relapsed or quiet state and BD with 








































































































































































































Figure 4.9: Detectable serum and saliva cytokine levels (pg/ml) of TNF-α, IL-2 and TNF-β. 
The mean concentration (pg/ml) of each individual cytokine were compared between HC, RAS, 
and BD patients with relapsed or quiet BD and BD with oral ulcer (U) and  BD without oral 
ulcer (NU) using one-way ANOVA and Mann–Whitney U-test. Bars represent mean values ± 




This revealed a difference in the amount of TNFα when RAS and BD-relapsed groups 
were compared (Fig3.9: p=0.0386) which was not apparent when all values were 
included. The limitation of the assay methodology will be discussed. 
 
Similarly, analysis of Salivary IL-6 (Fig 4.10) revealed significant differences between 
HC and BD-RE (p=0.0104) and also HC and patients with ulcers (p=0.0183). Levels of 
IL-6 were greater in relapsed patients compared with quiet patients (p=0.0080). Patients 
with ulcers also appear to produce a great deal more IL-6 than those without ulcers 
(p=0.0272). RAS patients had lower levels of IL-6 than BD-RE but this failed to reach 
significance (p=0.0517). There were significant differences in the variances (F test) in 



















































































































































































































Figure 4.10: Detectable saliva cytokine levels (pg/ml) of IL-6, IL-1β, IL-12p70, IFN-γ, and 
saliva and serum level of IL-8. The mean concentration (pg/ml) of each individual cytokine 
were compared between HC, RAS, and BD patients with Relapsed or quiet BD and BD with 
oral ulcer (U) and  BD without oral ulcer (NU) using one-way ANOVA and Mann–Whitney U-
test. Bars represent mean values ± SEM of all samples in each investigated group.  





4.1.3 Cytokine secretion profile following stimulation of PBMCs with HSP70 
In order to understand the possible role of HSP70 in aetiology of BD, PBMCs of HCs 
(n=10), BD-RE (n=5) and BD-Q (n=8) were stimulated with 10µg/ml Human HSP70 
for 24hours, and the cytokine secretion profile in supernatant was quantified using 
multiplex bead analysis detection system (see Chapter 2 section 2.4.5.1). Demographic 
characteristics and clinical features of investigated patients are summarized in Table 
4.4. 
Demographic and Clinical Features of the Investigated Patients(n=13) 
Mean Age ±SD 40.5±13.7(19-63) 
Gender n                                              % 
Male 5 38.5 
Female 8 61.5 
Clinical Features 
Oral Ulcers 9 69.2 
Genital Ulcers 3 23.1 
Eye Lesions 2 15.4 
Skin Lesions 7 53.8 
Joint involvement 8 61.5 
Encephalitis 2 15.4 
CNS 2 15.4 
Relapsed 2 15.4 
Treatment 
Prednisolone 4 30.8 
Azathioprine 5 38.5 
Colchicine 5 38.5 
No treatment 1 7.7 
Table 4.4: Demographic characteristics, clinical features and immunosuppressive drug 
treatment of investigated BD patients at the time of Blood collection. 
 
The data on the levels of detectable cytokines were compared amongst HC, BD quiet 




using one-way ANOVA and Mann–Whitney U-test. Wilcoxon matched pairs test was 
used to compare the levels of cytokines in unstimulated compared to stimulated 
PBMCs. IFN-γ, IL-17, IL-4, IL-5 and TNF-β levels fell outside of the detection range 


















































































































Figure 4.11: PBMC cell cultures stimulation with 10µg/ml HSP70 for up to 24hours. The level 
of cytokines in supernatant was quantified using multiplex bead analysis assay. The results are 
expressed as pg/ml (a and b) or stimulation index (Mean concentration of IL-8 in stimulated 
cells divided by unstimulated). 
 (c). Bars represent mean values ± SEM of all samples in each investigated group. *p<0.05 
 
Following stimulation with Human HSP 70, IL-8 levels in both HCs and BD samples, 
significantly up regulated at p=0.0313 and p=0.0171 respectively but in RE failed to 




measured in unstimulated cells (ANOVA P=0.0966), and cultures of BD-RE cells 
produced more IL-8 than HC (p=0.0303). Overall Combined BD compared to HC was 
also significant (p=0.0201). Following stimulation with Human HSP70 all cultures were 
induced to secrete IL-8 (ANOVA: P= 0.3996; Fig 4.11 a). However, if the stimulation 
index (SI: Fig 4.11c) was compared this was much lower in the BD patients than in the 
HC, suggesting that the already high levels of secretion of IL-8 in these cultures could 
not be further stimulated with Human HSP70. BD or RE displayed a significant 
decrease in comparison to HC (p=0.0201 and p=0.0303 respectively: Figure 4.11 b and 
c).  
 
Secretion of IL-10 was also investigated (Figure 4.12). There was no significant 
differences in the spontaneous secretion of IL-10 in unstimulated cultures (Fig 4.12b, 
ANOVA: P=0.4597). Following HSP70 stimulation, IL-10 levels significantly increased 
in HCs and BD (Fig 3.12 a, p=0.0313 and p=0.0156 respectively). However, the levels 
in the healthy controls were much higher than those in any of the stimulated BD groups 
following stimulation. Mean levels in the healthy controls were 1197±442.5 pg/ml, 
whereas the mean level in the BD groups only reached 166.8±79.89 pg/ml in the 
relapsed patients. Measurement of the stimulation index again suggested that BD cells 






























































































































Figure 4.12: PBMC cell cultures stimulation with 10µg/ml HSP70 up to 24hours. The level of 
IL-10(pg/ml) in supernatant was quantified using multiplex bead analysis assay. The results for 
stimulated IL-10 expressed as stimulation index. Bars represent mean values ± SEM of all 








4.1.4 ELISPOT Results 
The Possible role of Th17 cells in pathogenesis of BD has been subjected in several 
studies. The significant elevated levels of IL-23p19 mRNA expression, IL-23, IL-17, 
and IFN-γ in BD patients with active uveitis has been reported (Chi et al., 2008). In 
GWAS studies , the strong association of IL-23 receptor (IL-23R) genes with BD has 
been reported (Mizuki et al., 2010, Remmers et al., 2010). Moreover, the strong 
relationship between polymorphisms of IL23R and IL17 and BD has been reported 
(Jiang et al., 2010, Kim et al., 2012). Therefore, Secretion of the key cytokines of Th17 
cells in PBMCs was investigated using ELISPOT analysis. This technique is very useful 
in that it enables enumeration of cells actively secreting cytokines but has the 
disadvantage of using quite large numbers of cells. IL6, IL17 and IL12p70/23 capture 
antibodies were used to coat PVDF plates and the cells were either left unstimulated or 
stimulated for 24 hours with either PHA or Human HSP70 (HEK70). The results were 




4.1.4.1 IL-6 secreting cells 
There was some spontaneous secretion of IL-6 in 1 out of the six samples tested (80 
CSC/10
6
). There was some secretion following stimulation with HSP70, with two 
samples giving 115 and 291 CSC/10
6
 PBMCs respectively. Stimulation with PHA 
induced very high numbers of IL-6 secreting cells in 2 out of 5 of the samples tested 
(1000 and 2000 CSC). However in one of the samples the density of the spots was too 
great to count and in two other samples the background made counting difficult and 
these samples were scored as zero (Fig 4.13 a). In the BD samples there was also some 
spontaneous secretion ranging from 15 CSC to 77 CSC/10
6
 PBMC. Stimulation with 
either HEK or PHA induced further secretion but while this failed to reach significance 


























































































































































































Figure 4.13: Cytokines secreting cells in PBMCs. The results are expressed as Cytokine 
Secreting Cells (CSC)/10
6 
PBMCs. Healthy controls (n=6), BD (n=17 for IL-17 and n=27 for 
IL-6 and IL-12p70/23) were stimulated with PHA or Human HSP70 (HEK) and compared with 
unstimulated cells.  
 
(n=27, p= 0.005). Only two samples were able to be tested in the RAS group and the 
range of CSC in unstimulated cells gave 54 and 77 CSC, while HEK stimulation 
resulted in 82 and 102 CSC and PHA values were 104 and 83 respectively. Because of 




and BD in either unstimulated cultures or cells stimulated with HEK or PHA (Mann-
Whitney p= 0.2838, p=0.8212 and p=0.9363 respectively). 
 
4.1.4.2 IL-17 secreting cells: 
Only 1 BD patient out of 17 tested gave spontaneous secretion of IL-17 (130 CSC/10
6 
PBMCs). Stimulation with HSP70 (HEK) or PHA showed no significant difference 
between HC and BD. There was a significant difference between both unstimulated 
cells and those either stimulated with HEK or PHA (Wilcoxon, p=0.002 and p=0.0093 
respectively) demonstrating that the cells were capable of producing this cytokine (Fig 
4.13b).  
 
4.1.4.3 IL-12p70/23 secreting cells 
There were no significant differences between unstimulated cells and HEK stimulated 
ones in both HCs and BD (Wilcoxon p=0.156 and p=0.5 respectively) while following 
stimulation with PHA significant increase in IL-12p70/23 secreting cells was seen 
(Wilcoxon P=0.05 and P=0.03 respectively)(Fig 4.13c). Furtheremore there were no 
significant differences between HCs and BD both in spontaneous secretion of  IL-
12p70/23 (Mann-Whitney, p=0.188) and following stimulation with HSP70 (HEK) or 
PHA (Mann-Whitney, p=0.88, p=0.151 respectively).  
 
Taken together, these results indicate that the BD cells were less able to respond to 
stimulation by HSP70(HEK). Furthermore , there was no significant differences in the 
number of IL6, IL17 and IL12p70/23 secreting cells, between controls and BD both 

















Chapter 5: STAT Phosphorylation profile 
5.1 Human Phospho-Kinase Array 
In order to analyse the phosphorylation profiles of kinases and their protein substrates in 
BD, the relative levels of protein phosphorylation of the PBMCs from BD patients 
(n=6) in comparison to HCs (n=3) and RAS (n=3) were quantified using Human 
Phospho-Kinase Array in a pilot study (Figure5.1). The demographic and clinical 
features of the investigated patients are presented in Table 5.1. Of the 6 studied patients 
three were fully relapsed, one was fully quiet and the other two were generally quiet but 
one had activity in eye and the other in mouth, joints and skin. All the patients were on 
immunosuppressant treatments (Table 5.1).  
Patient Sex Age Active sites Relapsed Treatment 
P1 Male 50 All quiet No Azathioprine 
P2 Male 47 Eye No 
Prednisolone 
Azathioprine 
P3 Male 57 Mouth-Joints-Skin No 
Prednisolone 
Colchicine 
P4 Female 51 Mouth-Genital-Joints Yes 
Prednisolone 
CellCept 
P5 Male 52 Mouth-Eye-Joints-Encephalitis Yes 
Prednisolone 
Colcicine 
P6 Female 27 Mouth-Genital-Joints Yes 
Preinisolone 
Colchicine 






Figure5.1: Multiplex detection of phosphorylated proteins in cell lysates from HCs (A), RAS-
active (B), BD-quiet(C) and BD-relapsed (D) by Human Phospho-Kinase Array.  
1: STAT1 2: STAT2 3:STAT3 4: STAT4 5: STAT5 6:STAT6  
 
The data on the relative levels of protein phosphorylation from BD patients were 
compared with HC and RAS and also with disease activity in BD, quiet and relapsed, 
using ANOVA and Mann–Whitney U-test (Figures 5.2-5.8). As can be seen from 
Figures 5.2, with the exception of STAT 6, all the STATs displayed a noticeable 
difference in BD patients compared to healthy controls. The mean relative pixel density 
of STAT6 in BD (15.26±3.009) were greater than HCs (8.63±0.6714) but failed to reach 
significance (p=0.3810). Interestingly STAT 6 is associated with Th2 differentiation 




STAT4 were significantly increased in BD compared to HCs at p=0.0476, p=0.0467 and 
p=0.0238 respectively. Increased phosphorylation of STAT 1 and 4 would be consistent 
with activation of a Th1 differentiation pathway, while STAT 2 is associated with the 
defence against virus. STAT3 has also shown a marked difference between study 
groups (ANOVA, P=0.0213). Significantly higher expression of STAT3 was observed 
in BD compared to both HCs and RAS samples each at p= 0.0238. This would be 
consistent with a Th17 profile. It was interesting to observe that in this respect RAS 
behaved in a similar manner to HC. All the STAT5 proteins: STAT 5a, STAT 5b and 
STAT 5a/b displayed significant rise in BD patients compared to HCs all at p=0.0476 





Figure 5.2: The relative expression of phosphorylated proteins, STAT1, STAT2, STAT3, 
STAT4, STAT5 and STAT6 in PBMC were quantified by Human Phospho-Kinase Array. The 
mean relative pixel density was compared between HC, RAS, and BD patients with relapsed or 
quiet BD using one-way ANOVA and Mann–Whitney U-test. Bars represent mean values ± 



































































































































































































































































Although our main interest was the STAT proteins in this project, using the Proteome 
Profiler Human Phospho-Kinase Array, we were able to look at a total of 43 kinase 
phosphorylation sites and have identified 7 new, and as far as we are aware, previously 
unidentified kinase phosphorylation sites which may be altered in Behçet’s disease 
compared to HC and RAS. As can be seen from Figure 5.4, AMPKa1 and CRBE 
revealed significant increase in BD compared to HCs at p=0.0476 and p=0.0238 
respectively. Similarly, Yes showed the same trend at p=0.0238. Another interesting 
marker Fyn, displayed very remarkable differences between the studied groups 
(ANOVA, p=0.0021). Fyn were significantly higher in BD patients compared to HC (p= 
0.0126). Further analysis of Fyn relative pixel density also showed a significant increase 
in both relapsed and quiet compared to HC at p=0.0048 and p=0.0298 5 respectively.  
Fgr and FAK are another two protein tyrosine kinases which show a considerable 
differences in BD (ANOVA, P=0.0218 and P=0.0342 respectively). Fgr was 
significantly increased in BD patients compared to HCs and RAS at p=0.0238. 
Similarly, FAK showed a significant rise in BD compared to HCs at p=0.0238 and to 
RAS at p=0.0476 and finally RASK123 also showed significant rise in BD compared 
with HCs at p= 0.0238. 
Further investigations are needed since the sample size was quite small. The 
significance of the changes in these phosphor kinase proteins will be discussed in 
Chapter 6. Graphs of the remaining phosphor-kinase activities where no significant 








































































































































































































































































Figure 5.3: The relative expression of 8 phosphorylated proteins, in PBMC were quantified by 
Human Phospho-Kinase Array. The mean relative pixel density was compared between HC, 
RAS, and BD patients with relapsed or quiet BD using one-way ANOVA and Mann–Whitney 





Overall, using the Human Phospho-Kinase Array, the relative levels of 46 kinase 
phosphorylation sites in BD patients compared to HCs and RAS volunteers were able to 
be detected simultaneously. STAT1, STAT2, STAT3, STAT4 and STAT5 all displayed 
significant increase in BD patient compared to HCs. Furthermore, AMPKa1, CRBE, 
YES, FYN, Fgr, FAK and RASK123 showed a difference in BD and can be considered 
as  new targets in BD for future investigations. To our knowledge these proteins have 
not been investigated in BD to date. 
5.2 Phospho-specific flowcytometry results 
In order to investigate key transcription factors in the differentiation of Th1 and Th17 
cell signalling pathways a novel technique which uses Flow cytometry to measure 
STATs and their transcription factors in specific T cell subsets was used. Using this 
method allowed us to identify the subset of T cells expressing the transcription factors. 
The transcription factor RORγt is associated with Th17 differentiation and is closely 
linked with STSAT3, while T-bet controls Th1 differentiation and is associated with 
STAT1 and 4. Phospho-specific flowcytometry was used to investigate phosphorylation 
status of STAT1, STAT2, STAT3, STAT5 and the transcription factors t-bet and 
RORt in CD4
+
 T Cells isolated from PBMCs following activation with IFN-α  for 
15min  at 37°C.  This method enables the investigation of specific T cell subsets as 
compared with the phosphor array method which utilised PBMCs. 
 
The investigated samples include HCs (n=7), BD-Q (n=8) and BD-RE (n=8). The 
demographic and clinical features of investigated BD patients are presented in Table 
5.2. Of the 15 investigated BD patients, 5 male and 10 were female. The most frequent 
clinical symptoms were joint involvement (68.8%), CNS (62.5%) oral ulcers (50%) and 




Demographic and Clinical Features of the Investigated Patients(n=15) 
Mean Age ±SD 41.60±15.8(17-74) 
Gender n                                              % 
Male 5 31.3 
Female 10 62.5 
Clinical Features 
Oral Ulcers 8 50 
Genital Ulcers 4 24 
Eye Lesions 2 12.5 
Skin Lesions 3 18.8 
Joint involvement 11 68.8 
Encephalitis 1 6.3 
CNS(Headache) 10 62.5 
Vascular 1 6.3 
Relapse 8 50 
Treatment 
Prednisolone 4 25 
Azathioprine 5 31.8 
Colchicine 3 18.8 
CELLCEPT 1 6.3 
Table 5.4: Demographic characteristics, clinical features and immunosuppressive drug 
treatment of investigated BD patients at the time of serum collection for Phospho-specific flow 
cytometry. 
 
PBMCs were either stimulated with IFNα or left unstimulated for 15 minutes after 
which they were fixed and permeabilized and stained with antibodies specific for the 
STATs and transcription factors as described in Chapter 2 section 2.4.6. The cells were 
counter stained with CD4 antibody and the cells were gated in the FACS machine on 
the CD4
+
 population. Flow cytometry was carried out using a FACS canto II (BD 
biosciences, UK) and was later analysed with the Flow-Jo software (BD biosciences, 
UK). A representative gating stategy is shown in Figure 5.4.  The gate was first set for 








(Figure 5.4b). The difference in the overlay represents the isotype control in blue and 
the STAT5 staining in red. 
 
Figure 5.4: Representative FACS gating strategy: A) Forward and side scatted of total PBMCs. 




cell population. C) Overlay of Isotype control with anti 
phosphoSTAT5 antibody.  
 
The results were initially expressed as median fluorescent intensity or as a percentage of 
maximum fluorescence (Figure 5.5). As can be seen in the case of the STAT proteins 



































































































































































































































































Figure 5.5: Percentage expression of STATs and T-bet following stimulation with IFNα. The 
results were analysed using ANOVA and paired t tests to examine the differences following 
stimulation. Bars represent mean values ± SEM of all samples in each investigated group. 
* p<0.05, **p<0.01 
 
only [BD-Q (MA], however the difference just failed to reach significance (p=0.0651). 
A comparison of the levels of STAT3 in patients who were mouth active only with fully 
relapsed patients revealed a highly significant difference (p=0.0286). Investigation of 




relapsed patients showed differences which were close to statistical significance 
(p=0.0550). 
  
Because the percentage expression was highly variable the results were difficult to 
interpret and therefore, stimulation index (SI) was used to interrogate the results. 
Stimulation index (SI) i.e. MFI (Mean Fluorescence Intensity) of the stimulated cells 
divided by the unstimulated cells from BD patients were compared with HCs and also 
with disease activity: quiet and relapsed using ANOVA and Mann–Whitney U-test 
(Figures 5.6-5.8). Two separate sets of experiments were carried out.  
 
 In the first series of experiments [E1(Experiment 1): Fig 5.6] phosphorylated STAT1, 3 
and 5 along with transcription factor T-bet were examined in HC compared with quiet 
and fully relapsed BD as well as patients with mouth activity only [BD-Q(MA)]. As can 
be seen, pSTAT1 displayed higher expression in BD than HCs. The mean stimulation 
index of pSTAT1 in BD-RE (13.77±8.1) was greater than BD-Q (9.917 ±7) and HCs 
(2.764±1.3) but they failed to reach significance. There were no noticeable differences 
in pSTAT 3 and pSTAT 5 between study groups (ANOVA, P=0.9684 and P= 0.9958 
respectively). The mean stimulation index of pSTAT5 was lower in BD-RE (6.805±3.6) 
compared to HCs (9.641 ± 8.6) but it failed to reach significance. The most remarkable 
result of this experiment was increased level of T-bet in BD-RE compared to BD-Q at 





































































































































 Figure 5.6: Expression of pSTAT1, pSTAT3, pSTAT5 and T- bet in CD4+ T cells. PBMCs 
were stimulated with 1.8×10
8
 units/mg IFN-α for 15min at 37°C. Expression of pSTAT1, 
pSTAT3, pSTAT5 and t- bet in CD4+ T cells were investigated using Phospho-specific flow 
cytometry method. Mean stimulation index from HCs were compared to BD-Q and BD-RE 
using one-way ANOVA and Mann–Whitney U-test. Bars represent mean values ± SEM of all 






Figure 5.7: Percentage expression of RORγt, STAT1, 3 and 5 following stimulation with IFNα. 
The results were analysed using ANOVA and paired t tests to examine the differences following 
stimulation. Bars represent mean values ± SEM of all samples in each investigated group.  
tu: T cell unstimulated, ts: T cell stimulated with INFα 
 
In a second series of experiments [E2 (Experiment2): Fig 5.8] the comparison of 
phosphorylated STAT1, 3 and 5 along with transcription factor RORγt were shown. 
pSTAT1 results confirmed E1 experiment and show higher level in BD than HCs at p= 
0.6828. Again there were no significant difference in pSTAT3 and pSTAT5 between 
investigated groups (ANOVA, P= 0.5293 and P= 0.2913) respectively. RORγt slightly 





































































































































































































































































































































  Figure 5.8: Expression of pSTAT1, pSTAT3, pSTAT5 and RORγt in CD4+ T cells. PBMCs 
were stimulated with 1.8×10
8
 units/mg IFN-α for 15min at 37°C. Expression of pSTAT1, 
pSTAT3, pSTAT5 and RORγt in CD4+ T cells were investigated using Phospho-specific flow 
cytometry method. Mean stimulation index from HCs were compared to BD-Q and BD-RE 
using one-way ANOVA and Mann–Whitney U-test. Bars represent mean values ± SEM of all 
samples in each investigated group.  
 
The data for pSTAT 1, pSTAT3 and pSTAT5 in experiments 1 and 2 were combined to 
increase sample number and their results are shown in Figure 5.9 and 5.10. Similar 




The percentage expression is shown in Fig 5.9 and it can be seen that STAT1 and 
STAT5 show significant upregulation on stimulation with IFNα. STAT 3 did not shown 



















































































































































































































































































Figure 5.9: Percentage expression of T-Bet, RORγt and phospho-STATs 1, 3 and 5 in PBMCs 
following stimulation with IFNα. ANOVA and paired t tests were used to analyse the data.        
* p<0.05, **p<0.01  
 st: stimulated with INFα, un: unstimulated 
 
The data was combined from the two series of experiments for STATs 1, 3 and 5 and 



































































































Figure 5.10: Expression of pSTAT1, pSTAT3 and pSTAT5 in CD4+ T cells were investigated 
using Phospho-specific flow cytometry method. PBMCs were stimulated with 1.8×10
8
 units/mg 
IFN-α for 15min at 37°C. Mean stimulation index from HCs were compared to BD-Q and BD-
RE using one-way ANOVA and Mann–Whitney U-test. Bars represent mean values ± SEM of 









































Chapter 6 Discussion 
6.1 SOCS expression and Behçet’s disease 
Although the aetiopathogenesis of Behcet's disease is still unknown, immune 
dysfunction seems to be involved. It is generally accepted that cytokines play a key 
pathogenic role in BD. Several cytokines associated with BD such as IFNγ, IL-12, IL-
23, IL-10 and IL-6 have their effect through activation of JAK-STAT signalling 
pathway. This pathway is tightly regulated by SOCS proteins to avoid excessive 
immune responses and pathogenic consequences in the host. In this respect, any 
dysregulation in this balance can affect cellular responsiveness to cytokines and cause 
subsequent pathological effects. 
 
The implication of SOCS protein in human disease has been reported in several studies. 
Higher levels of SOCS3 mRNA and SOCS1 SNPs in T cells have been associated with 
asthma pathogenesis. These SNPs in SOCS1 are associated with increased SOCS1 
mRNA levels compared to healthy controls have been reported in the skin of patients 
with atopic dermatitis (Harada et al., 2007). The studies of mice deficient in SOCS1 
signalling develop severe skin and eye lesions through the recruitment of Th1 and Th17 
cells into these non-lymphoid tissues (Yu et al., 2008). SOCS3 gene deficient mice 
developed  a severe form of skin inflammation (Uto-Konomi et al., 2012). Some of the 
characteristic of Behçet’s disease is Eye and skin lesions. On our knowledge, SOCS 
protein expression has not been investigated in neutrophils and oral ulcers of BD 
patients to date. Therefore, SOCS expression in PBMCs, neutrophils and buccal 
mucosal cells of patient with BD were investigated in this project. Our results showed 
altered level of mRNA expression of SOCS in BD. In PBMCs, SOCS1 message was 




subgroups of BD separately showed significantly higher mean levels of SOCS1 but no 
significant differences were observed between quiet and relapsed patients. Similarly, 
neutrophils displayed higher levels of SOCS1 in BD patients, but the results failed to 
reach significance. For SOCS3, a significant upregulation in both PBMC and 
neutrophils of BD patients and also RAS compared to HC was seen. There was no 
significant difference in SOCS3 between relapsed and quiet patients. For SOCS2 
mRNA expression in PBMCs, BD relapsed patient displays a significant higher level 
than healthy controls and RAS. Surprisingly, SOCS2 level in neutrophils did not follow 
the same trend and hardly any changes between study groups were seen.  
 
Because BD patients frequently present with oral ulceration as the first symptom of 
their disease and ulcers are a dominant feature throughout the disease, special attention 
was given to the oral mucosa. mRNA expression of SOCS1 and 3 were also 
investigated in buccal mucosal cells (BMC) to compare matched ulcer and non-ulcer 
sites of BD patient. SOCS1 and SOCS3 have increased significantly in ulcer sites 
compared to non-ulcer sites and also compared to non-ulcerated healthy controls. The 
mean expression level of SOCS1 and 3 in non-ulcer sites were higher than HCs but it 
failed to reach significance. There were no significant differences of both SOCS1 and 3 
in non-ulcer sites comparing relapsed patients with quiet ones. This suggests that the 
non-ulcer sites are comparable to normal tissue in healthy controls. In ulcer sites, the 
relapsed patient displayed higher relative mean expression of SOCS1 and SOCS3 but 
both failed to reach significance. There is a significant upregulation of SOCS1 and 
SOCS3 in ulcer sites of quiet patients compared to their non-ulcer sites. Regarding 
relapsed patients, both SOCS1 and SOCS3 were also significantly increased in ulcer 





All these results showed a trend of higher levels of SOCS1 and SOCS3, especially in 
fully relapsed patients and in active oral ulcers which suggest that this might be the 
results of increased level of cytokines in BD and that upregulation of the negative 
regulators of cytokine signalling attempts to dampen down cytokine activation.  
 
In order to investigate post transcriptional regulation of SOCS1 and 3 in PBMCs and 
neutrophils from BD patients, western blot analysis was performed. SOCS2 protein was 
not detected in western blot. Generally SOCS2, in both qPCR and western blot was of 
low abundance and difficult to detect (data not shown). Thus, stimulation of cell 
cultures was needed to be able to detect them. SOCS1 protein expression displayed an 
increase in BD quiet compared to HCs, however the reverse was observed in BD-RE, 
which was decreased compared to HCs. No noticeable differences in SOCS3 protein 
expression between investigated groups was seen in PBMCs.  
 
Regarding the SOCS molecule and its function, broad studies have been recorded but 
very limited investigation was available on SOCS expression in pathological conditions, 
although, overexpression of SOCS proteins has been detected in other inflammatory and 
autoimmune diseases. Increased levels of SOCS3 in the  intestinal mucosa of  patients 
with Crohn’s disease has been reported (Suzuki et al., 2001). Like Behcet’s this is a 
disease of the mucosa and Crohn’s patients also exhibit oral manifestaions which might 
suggest a common pathway if SOCS disregulation in mucosal tissue undergoing 
pathological changes due to overt inflammation. Moreover, the level of SOCS1 and 
SOCS3 mRNA expression was significantly elevated in PBMCs from rheumatoid 
arthritis (RA) patients when compared with healthy volunteers (Isomäki et al., 2007). In 
a study on Th17 related cytokines and their signalling pathways in BD, significant 




following 24h PHA stimulation was observed (Shimizu et al., 2012). Significant 
upregulation of SOCS1 in PBMC in this project is in agreement with the Shimizu 
(2012) study; although they used PBMCs following stimulation with PHA while our 
experiments were done on unstimulated PBMC. The results of this project are also close 
to a similar study on the expression of SOCS in rheumatoid arthritis(Isomäki et al., 
2007), where significant upregulation of SOCS1 and SOCS3 were also found in 
inflammatory lesions in rheumatoid arthritis.  
 
There is controversy in interpreting these results. As discussed earlier, increased 
proinflammatory cytokines such as IL-6, TNF-α, IL-12 and IL-15 in BD have been 
reported. High level of these cytokines could lead to an increase of SOCS proteins 
which inhibit cytokine signalling and eventually supress the damaging effect of 
proinflammatory cytokines. On the other hand, SOCS proteins are also implicated in 
signalling pathways of anti-inflammatory cytokines such as IL-10, thus high level of 
SOCS might supress their function and promote more inflammation. 
 
There are some considerations which should be taken into account when interpreting 
data in SOCS studies. First SOCS proteins play a variety of roles in many other 
immunological processes. SOCS proteins along with STATs molecules have an 
important role in Th1 and Th2 cell differentiation.  SOCS1 has been shown as a 
negative regulator of IL-12, IFN-γ and STAT 4 signalling pathway (Eyles et al., 2002). 
SOCS3 deletion  in T cells,  indirectly suppresses both Th1 and Th2 cell responses, as a 
result of enhancing the levels of immunosuppressive cytokines TGF-β and IL-10 
(Kinjyo et al., 2006). Inhibition of STAT3 signalling by SOCS3 induce Th17 cells 
production (Palmer and Restifo, 2009). On the other hand, SOCS1 deletion results in 




2008). The role of SOCS proteins in innate immunity especially regarding TLRs was 
subjected to many investigations. TLRs signalling pathway should be controlled tightly 
since its uncontrolled activation leads to immunological and inflammatory disease. It 
has been shown that SOCS1 and SOCS3 proteins negatively regulate TLR signalling 
pathways (Naka et al., 2005). In a recent study from our group, splice variants of both 
TLR 2 and 4 have been shown to be increased in BD patients which may have an effect 
on their ability to respond to microbial antigens (Seoudi et al., 2013) . 
 
 
Secondly, considering other factors which might affect regulation of the JAK-STAT 
pathway, such as mechanisms required for regulating SOCS protein levels should be 
considered. There are limited studies about SOCS protein regulation, itself, in the 
literature. MicroRNAs (miRNAs) are small non-coding RNAs which act by binding to 
complementary sequences on target mRNAs and cause silencing of gene expression 
(Collins et al., 2013). In a recent study, the augmentation of JAK STAT signal 
transduction by miR-19a through control of SOCS3 expression has been shown (Collins 
et al., 2013). It has been suggested that miR-155 mediated SOCS1 suppression 
increases the JAK-STAT signaling required for Treg/Th17 cell differentiation, and also 
is associated with enhancing  IL-12 production in DCs (Collins et al., 2013).  
 
Thirdly, cytokine signalling pathways are not only controlled by SOCS proteins, but are 
also controlled by other molecules and negative regulation pathways. These include 
protein tyrosine phosphatase inhibitors such as SHP-1 and CD45 and the protein 
inhibitors of activated STATs (PIAS) (Krebs and Hilton, 2001). PIAS are a family of 
proteins which interact with many transcription factors in the immune system through 




recruiting transcriptional co-repressors and promoting protein sumoylation (Shuai, 2006 
). SHP-1 negatively regulates cytokine signalling pathways by binding via their SH2 
domains to phosphotyrosine residues of cytokine receptors and dephosphorylating 
signalling components such as the IL4 receptor, JAK2 (Wormald and Hilton, 2004). 
 
In this project, we encountered some limitations which may cause difficulties in 
interpretation of the results and needs to be considered for future experiments: 
1) RAS was used as a disease control in this project since their oral lesions are quite 
similar to BD. Unfortunately; we were not able to recruit a large number of volunteers 
to have reasonable sample size for robust statistical analysis. The reason for this is that, 
individuals who referred to dental hospital for treatment of RAS are reluctant to donate 
samples for research. We were therefore restricted to a small number of generous 
colleagues, with RAS, who were willing to donate samples.  Our BD patients were 
always very willing to donate samples (with the understandable exception of punch 
biopsies) and were always very interested in the research being carried out into their 
disease. Ideally, since most of the investigations in this project were systemic and on 
blood samples, samples from systemic auto immune or auto inflammatory diseases 
might make a more suitable disease control group.  
 
2) In this project the findings on mRNA expression by qPCR and protein relative 
measurements by western blot, had weak correlations. Generally protein concentration 
is nearly close to phenotypic level, expresses the physiological status of a cell. 
However, transcription regulation, due to the regulation control at different levels 
between transcription and translation, is insufficient by itself to completely describes 
protein abundance (MacKay et al., 2004). Several studies have been performed to 




imperfect and variable correlation between mRNA and protein levels (Shebl et al., 
2010). Therefore care must be taken in interpreting data about a protein when mRNA 
expression results are used. 
 
3) Since SOCS1 and SOCS3 levels are regulated by post-transcriptional mechanisms, 
the qPCR experiments on buccal mucosal cells for mRNA level should have been 
confirmed by other protein detection methods such as immunohistochemical staining of 
oral ulcer biopsies. Unfortunately, BD is a rare disease in the UK, and recruiting enough 
patients has been always a problem and biopsy material was scarce. There are several 
studies being carried out in the department and some information on the expression of 
SOCS by immunohistochemical staining was recently carried out by Dr Sonia 
Vartoukian. There is some evidence of increased staining of SOCS proteins on the 
borders of the epithelium close to ulcer lesions and also in the basal lamina propria (data 
not shown). These findings will be part of a joint publication which is to be submitted 
for publication.  
 
 4) One of our main problems in this project was the stratification of our patient cohort; 
first, recruiting BD patient without any medication or categorising them into groups 
with the same type and dose of medication and secondly classifying them in groups 
with similar clinical symptoms proved very difficult and resulted in very small 
subgroups . This would have made statistical analysis extremely difficult. 
 
5) There were some problems in sample preparation which could bias our results and 
gave some outliers and/or large standard deviations. As discuss earlier, BD is a rare 
disease in the UK and it takes time to gather enough cohort. For this reason  some of our 




samples may lead to some degradation and affect our results depending on type of the 
sample and the experimental method.  
 
Altogether, SOCS expression studies in this project showed considerable changes of 
SOCS1-3 in BD. However these alterations were different in different cell 
compartments.   In order to have a clearer picture of the SOCS function in BD, more 
experiments required looking at each individual cytokines and its pathway and 
comparing them with appropriate controls. However, the results do suggest the 
importance of investigating both the local environment of the oral mucosa and the 
systemic compartment together. 
 
It is not clear if the activity in the local oral mucosa influences systemic activity or vice 
versa. However, from a clinical perspective Professor Fortune has observed that those 
patient who are able to control their mouth ulcers seem to have fewer syetemic 
manifestaions (personal communication and unpublished observsations). 
 
6.2 Cytokines and Behçet disease 
Since one of the key immunological features of BD is alterations in cytokine levels, the 
investigation of cytokine profile in the serum or saliva of these patients helps to 
elucidate the aetiopathogenesis of BD and also might provide diagnostic or activity 
markers for the disease. Therefore, the serum cytokine profile in a UK cohort of 58 BD 
patients was investigated. Since many samples gave undetectable values and some had 
very large range of values, making comparisons were very difficult. Generally our 




healthy controls but all failed to reach significance. A similar study on serum cytokine 
profile of UK cohort has been done by Curnow et al., 2008. There are similarities and 
differences between the results of these studies. They found higher level of IL-8 and 
TNF-α in BD compared to HCs and lower level in relapsed than quiet patients which 
were in agreement with our findings. However they reported higher level of IL-6 as well 
which were undetectable in our experiments. However, we were able to detect high 
numbers of IL-6 secreting cells in BD samples using the ELISPOT method. On the 
other hand, while IL-10 and IL-4 were undetectable in the Curnow study, they were 
positive in 24 and 26 out of 79 of our samples respectively. We could not conclude any 
specific cytokine profile suggesting either a Th1 or Th2 profile, which was in agreement 
with the study of Curnow et al 2008, and also similar to previous findings of our group 
when investigating chemokine and cytokine expression in ulcers of BD patients 
(Dalghous et al., 2006). Other studies on serum cytokine level in BD have been 
controversial. Several studies have confirmed higher level of proinflammatory cytokines 
such as IL-1α, IL-1R, and IL-1β in the serum of patients with BD (Zhou et al., 2012, 
Düzgün et al., 2005). In addition, genetic studies have established significant 
association of IL‐1 polymorphism with increased susceptibility for BD (Karasneh et al., 
2003).Düzgün et al have reported significant higher serum level of TNF-α and its 
soluble receptor (TNFR1) in patient with active BD in comparison with controls 
(Düzgün et al., 2005). The association of TNF-α polymorphisms with Behçet’s disease 
in various ethnic groups supported the involvement of TNF-α (Touma et al., 2010). 
Evereklioglu et al reported significant higher level of IL-8 and TNF-α in active BD 
patients than those in inactive phases of the disease(Evereklioglu et al., 2002). This 
finding is completely different from Curnow et al., 2008 and our study. In our largest 
study, using 58 serum samples there appeared to be a small significant difference 




no IL-8 was detected and this may have skewed the result. If only those sample where 
IL-8 was detectable were compared, there was no difference. We further investigated a 
small cohort of matched serum and saliva samples and again there was no significant 
difference between BD quiet and relapsed. However, when PBMCs were cultured with 
or without Human HSP70 there was a significant differences in the levels of IL-8 
produced. The IL-8 level were significantly higher in unstimulated BD-RE cultures than 
the HCs while following stimulation, the stimulation index was significantly higher in 
HCs than BD suggesting that further stimulation of BD-RE could not induce further 
secretion of this pro-inflammatory cytokine. 
 
As stated earlier, Th1 cells are responsible for directing cell mediated immunity by 
releasing cytokines such as IFN-γ and IL-12. Most of the studies are in favour of Th1 
polarization of the immune response in Behcet’s disease (Frassanito et al., 1999, Zhou 
et al., 2012). In our study, IFN-γ and IL-12p70 was found in only 7 and 9 out of 79 
samples. The Curnow study supported our results and found very similar results.  
 
IL-4, IL-5, IL-13 and IL-10 are produced by Th2 cells to promote humoral immunity. 
Remmers (2010) reported the association of IL-10 variant with decreased levels of both 
mRNA and protein expression in BD (Remmers et al., 2010). Generally, there is no data 
regarding a possible role of IL-4, IL-5 in BD. Our results did not detect any IL-4 and 
IL-5 and mean level of IL-10 slightly decreased. In Curnow study IL-4 and IL-10 were 
undetectable. Although autoantibodies to several self-proteins are known to be induced 
in BD and these Th2 cytokines might support their production (Pineton de Chambrun et 
al., 2012). However, we were able to demonstrate a decreased ability of PBMC’s fro 




suggesting that the capacity for the production of suppressive cytokines is somehow 
depressed in BD compare with healthy controls. 
 
The cytokine analysis was repeated but this time with 37 matched serum and saliva 
samples. Interestingly, the range of cytokines in serum and saliva were very different 
and some seemed to be more abundant in the saliva than serum. Saliva IL-6 was 
significantly higher in BD patients and RAS compared to HCs. Saliva IL-6 levels were 
also significantly higher in relapsed BD versus quiet BD and was higher in the saliva of 
patients with ulcers than without it. Saliva TNF-α level was higher in BD relapsed and 
patient with oral ulcer compared with HCs. The data on salivary cytokine profile in 
Behçet disease is limited. In a study on salivary cytokines in patients with recurrent 
aphthous ulceration, significant differences in salivary TNF-α between healthy controls 
and patients with acute RAU especially during the remission period were found.(Boras 
et al., 2006).  They did not report any differences in salivary IL-6 between all three 
groups. Our data did not show any differences between RAS and healthy controls in 
both TNF-α and IL-6.  In the analysis of salivary cytokines the contribution of any 
serum transudate was not taken into account and in future experiments it would be 
important to measure the levels of serum albumin, for example, as a potential measure 
of the amount of transudation. Similarly the oral hygiene of patients needs to be 
monitored as levels of gibgivitis and periodontal disease will contribute to serum 
transudation. 
 
It has been suggested that HSP70 might mediate innate and adaptive immune responses 
and contribute in proinflammatory cytokine activation and tissue destruction in BD 
(Birtas-Atesoglu et al., 2008). HSP70 has ability to bind with high affinity to the plasma 




inflammatory cytokines such as TNF-α, IL-1β and IL-6 in human monocytes(Asea et 
al., 2000). Significant up regulation of both free human HSP70 and anti-HSP70 
antibodies in patients with BD have been observed (Birtas-Atesoglu et al., 2008). Our 
group has also shown that HSP70 was elevated in the saliva of BD patients and this 
correlated with serum IgG specific for the antigen (Bergmeier et al., 2009). As pointed 
out earlier, subcutaneous injection of HSP peptide 336-51with adjuvant and oral and 
nasal administration without adjuvant are able to induce experimental autoimmune 
uveitis in rats (Phipps et al., 2003). Furthermore, heat shock proteins have been 
considered as candidate self-antigens in Behçet’s disease. In this study, cytokine 
secretion profile was investigated in PBMCs from BD patients, following 24 hours 
stimulation with HSP70. It was demonstrated that anti-HSP70 antibodies can develop 
and  IL-8 and TNFα production was induced by HSP70 in human peripheral blood 
monocytes, possibly through activation via TLR-4 (Yokota et al., 2006a, Yokota et al., 
2006b). 
 
Surprisingly, IFN-γ, IL-17, IL-4, IL-5 and TNF-β all fell outside of the detection range. 
Both IL-8 and IL-10 were significantly upregulated following stimulation in HCs and 
BD cell cultures. Comparing study groups in unstimulated cells showed significant 
upregulation of IL-8 in BD-RE and overall combined BD compared with HCs. In 
contrast, following stimulation, BD or RE displayed a significant decrease in IL-8 in 
comparison to HCs which is contrary to expectations.  For IL-10, there was no 
significant difference in the spontaneous secretion of IL-10 in unstimulated cultures. 
Measurement of the stimulation index again showed significant decrease in BD 
compared to HCs suggesting that BD cells were less able to respond to stimulation by 





The results obtained from the cytokine profile experiments in BD (chapter 4) are in 
agreement with some of the previous studies but not all of them. There are several 
possible explanations for these differences and some contradictory results: 
 
1) There are complications in patient selection as Behçet disease is multi-systemic and 
recruiting patients who display only one organ involvement or similar multi organ 
involvements is difficult. Similarly, there are differences in categorizing patients in 
different studies. Some studies consider “active” as having activity in even one organ 
and some considering active or relapsed patient as having at least activity in three 
organs as described by the International Study Group. 
 
2) Our cohort was largely white British in origin, therefore the role of environmental or 
genetic factors in the aetiopathogenesis of BD will be different fromstudies carried out 
in other countries with different genetic an environmental backgrounds. The RAS 
subjects used in this study were self identified as healthy and their ulcers when present 
were all of the minor type. The subject were not on any medication for their condition. 
 
3) Using different methodologies is another important factor which affects comparing 
results from different experiments. ELISA techniques are widely accepted as the gold 
standard to quantify cytokine expression. ELISAs are well-matched for single parameter 
analysis, but it is time-consuming and expensive when performing multi-parameter 
analyses. A multiplex bead array assay (MBAA) was used in this project. This system is 
able to distinguish simultaneously up to 20 different protein targets in just single small 
volume sample. Moreover, MBAA assays are easy to perform and reproducible. 
Although the majority of studies have presented good correlations between MBAA and 




(possibly) the methods of comparison and the type of  antibodies  used (Elshal and 
McCoy, 2006). All in all, it is recommended that any study which involves consecutive 
follow up of patients, or samples from different time points, are better carried out using 
only a single technique, one platform, and one commercial company for all samples 
(Khan et al., 2004).  
 
4) Some of the differences in type of cytokines responses resulted from studies on 
cellular production of cytokines and following stimulations such as LPS or PHA. PHA 
is a polyclonal stimulator and while LPS is also able to activate many cell types it does 
so through specific binding to such molecules as CD14 and TLR4. Therefore the 
activation pathways and resulting cytokines may be very different. 
 
5) The effect of type of treatment in BD patient on cytokine responses is complicated. 
Azathioprine works by inhibiting purine synthesis, which is required for proliferation, 
and iNOS production, that leads to inhibition of  cell migration (Curnow et al., 2008). It 
has been suggested that Colchicine inhibits neutrophil activity and migration, but it does 
not affect CXCL8 levels (Miller EJ, 1993). As a result these drugs may inhibit the 
migration of leucocytes into inflammatory locations, but not essentially the chemokines 
and cytokines implicated in this process (Curnow et al., 2008). 
 
6) There are some important considerations in sample collection which cause variation 
in the results such as detection range, serum versus plasma, several rounds of freeze-
thawing and sample storage time. It has been shown that cytokines including IL-13, IL-
15, IL-17 and CXCL8 began to be degraded within one year of storage, while levels of 
IL-1α, IL-1β, IL-5, IL-6, and IL-10 were degraded by over 50% in 2-3 years (de Jager et 




saliva of BD patients which may contribute to loss of cytokines (data not shown). This 
needs to be further investigated. 
 
It is generally accepted that cytokines play critical roles in the initiation and 
perpetuation of Behçet disease. From this study, no classic Th1, Th2 or Th17 response 
was concluded. Higher levels of proinflammatory cytokines TNF-α and IL-β were 
observed. Serum IL-8 was in the past considered as a disease activity marker, since it 
has been shown to be significantly higher in quiet BD patient than relapsed (Durmazlar 
et al., 2009). However, the data in this nstudy does not support those findings. Salivary 
IL-6 can also consider as an activity marker in BD patient with oral ulcer. IL-6 has been 
associated with the incution of a Th17 profile but Th17 cytokines wer not readily 
detectable in this stusdy. Further investigation, especially functional assays is needed to 
understand the pathological and clinical effect of cytokines in BD.  
6.3 STAT Phosphorylation profile 
Cytoplasmic and nuclear transcription factors play an important role in regulation of T 
cell differentiation and cytokine pathways. The, STAT transcription factor family 
especially STAT1, STAT2, STAT3, STAT4, STAT5a/b and STAT6 are involved in 
modulating inflammatory responses. Apart from their important role in JAK-STAT 
signalling pathway, STATs gene family are critical for Th cells differentiation. It is now 
clear that this pathway might directly relate to human disease including Behçet’s 
disease. Polymorphisms of the genes encoding IL-23, JAK2, TYK2, and STAT3 have 
all been linked to autoimmune diseases such as psoriatic arthritis, Grave’s disease, 
Crohn’s disease and multiple sclerosis (o'shea and plunge 2012). GWAS studies have 




(Remmers et al., 2010). Therefore, transcriptional regulation of Th1/Th17 polarization 
in BD was investigated in this project.  
  
In order to activate and bind to DNA, most of transcription factors including STATs 
must be phosphorylated in advance. Thus, the phosphorylation profiles of kinases and 
their protein substrates were analysed in BD by the Proteome Profiler Human Phospho-
Kinase Array.  Using this method, we were able to look at a total of 38 kinase 
phosphorylation sites simultaneously. Our results showed marked difference of STATs 
family in BD patient compared to healthy controls. STAT1, STAT2, STAT3 and 
STAT4 were significantly higher in BD compared to HCs. STAT6 were greater in BD 
than HCs but failed to reach significance. All the STAT5 proteins: STAT 5a, STAT 5b 
and STAT 5a/b displayed a significant rise in BD patients compared to HCs.  
There are very a very limited number of publications regarding STATs activity in BD 
and the existing studies have been performed using different methodologies, therefore 
comparison of our results with previous findings were quite difficult. This study has 
attempted to investigate the transcription factors in PBMCs and in CD4
+
 T cells using 
two different mthodologies and our findings are interesting but not conclusive. 
 
The implication of the Th1 /Th17 polarization and increased level of Th1 or Th17 
cytokines in Behcet’s disease was subjected to several studies (Frassanito et al., 1999, 
Zhou et al., 2012). Recent studies have revealed simultaneous increased level of both 
Th1- and Th17- cytokines in these patients (Shimizu et al., 2012). 
Differentiation into Th1 cells is dependent on STAT1 and STAT4 acting via T-bet to 
produce the signature cytokine of Th1, namely IFNγ. This process is inhibited by 




STAT3 activation and is inhibited by SOCS 3 but stimulated by SOCS1. STAT 5 acts to 
upregulated the induction of Tregs through Foxp3 and is probably inhibited by SOCS1 
but the role of SOCS 3 is yet to be unraveled (Yoshimura et al 21012). The experiments 
carried out in this study were designed to investigate this profile in BD compared with 
HC and RAS subjects. 
The findings of the current study are consistent with previous studies confirming Th1- 
and Th17 polarization of BD. Increased phosphorylation of STAT 1 and 4 would be 
consistent with activation of a Th1 differentiation pathway and increased 
phosphorylation of STAT 3 is in accordance with Th17 differentiation pathway.  
From all the STATs, only STAT6 did not show any remarkable differences in BD. This 
result may be explained by the fact that STAT6 is involved in the development of Th2 
Cells differentiation and mediating responses to IL-4 and most of the previous studies 
did not suggested Th2 polarization in BD. Moreover, there is no data available 
regarding the possible role of classical Th2 cytokines; IL-4, IL-5 and IL-13 in BD. 10 
Our data showed significant upregulation of STAT5 proteins which are associated with 
Tregs differentiation, in BD. Increased number of  CD4+CD25+ Treg cells in the 
peripheral circulation of active BD patients have been reported (Hamzaoui et al., 
2006).They suggested that high level of  CD4+CD25+ T cells could be important in the 
regulatory process of the inflammation in active BD. The investigation of Tregs was 
beyond the scope of the project, but the results suggest the role of STAT 5 in the 
differentiation of these cells and would be a very interesting further study. 
 
It has been suggested that STAT 2 is associated with the defence against virus as 
STAT2 deficient mice display an increased susceptibility to viral infection (Park et al., 




needs to be confirmed using larger sample size and further methodology as no data has 
been reported so far. 
 
We identified seven new kinase phosphorylation sites including AMPKa1, Yes, Fyn, 
Fgr, FAK, RSK1/2/3 and CRBE which revealed significant increase in BD compared to 
HCs. To our knowledge these proteins have not been investigated in BD.  
Protein kinase (AMPK)-α1 has a key regulatory role in NF-κB-dependent gene 
expressions in inflammatory signalling mediated by and TNF-α  stimulation (Jung et al., 
2012) . The important role of proinflammatory cytokines including TNF-α in BD has 
been discussed earlier and TLR4 is the primary recognition molecule for LPS and HSP 
which both are considered as triggering factors in BD by driving TNFα production..  
 
Yes, Fyn and Fgr are the members of Src family kinase which are non-receptor tyrosine 
kinases. Many studies have shown the various roles of Src family in macrophage-
mediated innate immunity, such as phagocytosis, the production of inflammatory 
cytokines/mediators, and the induction of cellular migration (Byeon et al., 2012). In this 
respect investigation of these signalling molecules could be important in finding the 
pathogenesis of many inflammatory diseases. The infiltration of inflammatory cells into 
the oral mucosa might be dependent on the upregulation of these molecules. 
 
Ribosomal s6 kinase (rsk) is a family of protein kinases involved in signal transduction  
and regulates diverse cellular processes, such as cell growth, cell motility, cell survival  
and cell proliferation (Anjum and Blenis, 2008). Again, migration will be dependent on 
changes that allow cells to move through tissue and may be key to the infiltration of 




CREB (cAMP response element-binding protein) is another transcription factor and 
mostly investigated in brain. In neurons, a wide range of extracellular stimuli are able to 
activate CREB family members. CREB-dependent gene expression has been implicated 
in different functions ranging from development to implication in disease (Bonnie and 
David, 2002). Since many aspecst of the pathology of BD involve neurological 
involvement, this might be a signature of this end of the BD spectrum of pathologies.  
These results were very exciting as they have revealed new targets of investigation and 
may also reveal drug targets for better management of the disease. 
We  analysed phosphorylation status of STAT1, STAT2, STAT3, STAT5 and the 
transcription factors T-bet and RORγt in CD4
+
 T Cells following activation with IFN-α. 
STAT1, STAT5a and STAT5b showed significant upregulation following stimulation 
with IFNα but STAT 3 did not show any change following stimulation.  
 
Our finding did not revealed any significant differences in pSTAT 3 and pSTAT 5   
between study groups. We found lower mean stimulation index of pSTAT5 in BD-RE 
in comparison to HCs but it failed to reach significance. T-bet showed higher level in 
BD-RE compared to BD-Q and RORγt slightly increased in BD compared to HCs but 
both just failed to reach significance.  
 
JAK-STAT signalling is one of the best characterized IFN-signalling pathways (Stark, 
2007).  IFN-α can activate several members of the STAT transcription factor family. 






In a study on 73 BD patients in Tunisia , significant higher levels of mRNA relative 
expression for IL-17 and RORγt in active BD patients when compared to healthy 
controls and to remission BD patients has been reported (Hamzaoui et al., 2011). In a 
study by Li (2003), upregulation of T-bet mRNA was detected in BD patients compared 
to controls but no significant difference was found between BD patients with active 
uveitis and normal controls regarding the expression of either T-bet mRNA or its 
protein after stimulation with PHA (Li et al., 2003).  
 
The results of these two methods did not support each other. Proteome profiler is a semi 
quantitative assay with multi analyse profiling but less sensitive while Phosflow is 
quantitative, single cell analysis method with high sensitivity. In Proteome profiler we 
looked at PBMCs but in Phosflow analysis CD4+Tcells were considered. Moreover in 
Proteome profiler, only three samples were examined in each study group while in 
Phosflow; around eight samples exist in each group.  To gain comprehensive results, 
more preliminary optimization experiments and larger sample size are needed.  
 
7: Conclusion and Future work 
The present study was designed to determine the SOCS expression in Behçet’s disease. 
Altogether, SOCS 1-3 expression showed considerable changes in Behçet’s disease. 
Up-regulation of SOCS expression might considerably affect cellular reaction to 
antiinflammatory cytokines in BD which leads to disease progression. 
.However these alterations were quite different in different cell compartments and  
localization.  This is an important observation as using peripheral blood to investigate 
disease in local tissues may not give correct information. In order to have clearer picture 




cytokine pathway and its regulation by SOCS and comparing them with appropriate 
controls. 
From cytokine studies in this project, no classic Th1, Th2 or Th17 response was 
concluded. Higher levels of proinflammatory cytokines TNF-α and IL-β were 
observed.. Salivary IL-6 can also be considered as an activity marker in BD patient with 
oral ulceration. Further investigations, especially functional assays are needed to 
understand the pathological and clinical effect of cytokines in BD.  
 
This project showed significant upregulation of STAT1, STAT2, STAT3, STAT4 and 
STAT5 in BD compared to HCs which is  consistent with involvement of a Th1, Th17 
and Treg cells differentiation pathways. 
 
We identified seven new kinase phosphorylation sites including AMPKa1, Yes, Fyn, 
Fgr, FAK, RASK123 and CRBE in BD, all involve in signalling pathways of 
inflammatory cytokines and mediators. To our knowledge these proteins have not been 
investigated in BD. 
 
Addressing cytokine regulation will greatly boost our understanding of the immune 
pathogenesis of Behçet’s disease and may considerably contribute to the study on 
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Appendix 2: Patient Invitation Information 
INVITATION TO PARTICIPATE (Patients)   
Immunoregulation at the mucosal barrier (Version 1:  February 2004) 
Bart’s and The London Queen Mary’s School of Medicine and Dentistry, University of 
London  
We invite you to take part in a research study which we think may be important. The 
information which follows tells you about it.  It is important that you understand what is 
in this leaflet. It says what will happen if you take part and what the risks might be. Try 
to make sure you know what will happen to you if you decide to take part. Whether or 
not you do take part is entirely your choice and any decision will not affect the 
treatment you receive. Please ask any questions you want to about the research and we 
will try our best to answer them. 
Why have we approached you? 
You have been invited to participate in this study because you have an inflammatory 
condition which may affect the mouth. We wish to collect some tissue from your mouth 
(biopsy), saliva, urine and blood samples. 
This is because we think that inflammation in the mouth causing ulceration may have a 
more widespread effect in determining whether you may develop other features of your 
particular illness. Mouth ulceration may predict severity or activation of your disease. 
You are unlikely to benefit directly from this research yourself, but we hope that the 
results of these studies will benefit similar patients in the future. 
 
What would I do in the study if I took part? 
If you agree to participate in this study you will initially be asked to complete a 
confidential health questionnaire; you will also undergo a physical examination, 




blood sample from your arm (about an egg-cup full, 50 ml), a samples of spit (1/2 egg 
cup, 25 ml) and a urine sample (10 ml). A drug of abuse screen will also be performed
  
If you are female, we will ask your permission to perform a pregnancy test; we would 
prefer that you do not to take part in this study if you are pregnant. None of the tests we 
intend to do will harm an unborn baby, but the mucosa (tissue) heals less well in 
pregnancy. We would prefer to avoid biopsies in pregnancy unless absolutely necessary. 
Please inform us if you think you may be pregnant. 
 
There are several components to the study: 
On entry to the study we will take a blood sample and saliva. The blood sample will be 
taken as part of your routine screen. We will take 50 ml (1 egg cup full) of blood, 25 ml 
(1/2 egg-cup) of spit and 10ml of urine. Blood tests may cause a very small discomfort 
when the needle is put into the vein, but this is momentary. The saliva will be collected 
by asking you to spit into a small container over a period of not more than 5 mins. You 
will collect the urine sample in private. 
Another two blood tests requiring the same amount of blood will be taken over the 
period of study.  
A small mouth biopsy (6 mm, about the size of the tip of your small finger).will be 
taken from the inside of your cheek or lip in an area where there is an ulcer or the tissue 
is very inflamed. You will be given a pain killing injection which will numb the area to 
be biopsied. This is similar to having an injection at your dentist. This painkilling 
injection does sting, but only momentarily, and it is very effective and works quickly. 
You will not be able to feel any discomfort for the rest of the procedure. A stitch will be 
used to hold the mucosa together afterwards; this will need to be removed by us 10 days 




using molecular or cellular technology. We would like to see what is happening in the 
inflamed and ulcerated areas.   
You are very unlikely to develop any problems following the above tests. Very 
occasionally, however, a mucosal biopsy or a blood test can be associated with bruising, 
bleeding or infection. 
The above tests will involve you attending either the Royal London Hospital or St. 
Thomas’ Hospital depending on where you are registered as a patient.     
If you have any questions concerning this study please feel free to ask us .We can 
provide you with further information if you wish. Contact names and telephone 
numbers are given below. 
Tissue samples taken from you may be stored for a period of no more than 5 years, and 
will not be used for any other purposes other than this study. 
Similarly, any blood samples taken from you will only be used for this study. 
You don’t have to join the study. You are free to decide not to be in this trial or to drop 
out at any time.  If you decide not to be in the study, or drop out, this will not put at risk 
your ordinary medical care. 
What happens if you are worried or if there is an emergency? You will always be able 
to contact an investigator to discuss your concerns and/or to get help: 
  
Name:  Prof.F.Fortune 
Address:   Centre for Clinical and diagnostic Oral Science, Clinical Sciences 
Building, 2 Newark Street, London E1 2AT  
Telephone number: 020-7882 7154/8 
 




We believe that this study is basically safe and do not expect you to suffer any harm or 
injury because of your participation in it. However, Barts and The London NHS Trust 
has agreed that if your health does suffer as a result of your being in the study then you 
will be compensated. In such a situation, you will not have to prove that the harm or 
injury which affects you is anyone’s fault. If you are not happy with any proposed 




Appendix 3: Healthy Volunteer Information 
INVITATION TO PARTICIPATE (Healthy Volunteers)  
IMMUNOREGULATIONAT THE MUCOSAL BARRIER 
Bart’s and The London Queen Mary’s School of Medicine and Dentistry, University of 
London 
Version 1:  February 2004 
We invite you to take part in a research study which we think may be important. The 
information which follows tells you about it.  It is important that you understand what is 
in this leaflet. It says what will happen if you take part and what the risks might be. Try 
to make sure you know what will happen to you if you decide to take part. Whether or 
not you do take part is entirely your choice. Please ask any questions you want to about 
the research and we will try our best to answer them.  
You have been invited to participate in this study because you are a healthy individual.  
We wish to collect some tissue from your mouth (biopsy), saliva, urine and blood 
samples. 
This is because we think that inflammation in the mouth may have a more widespread 
effect in determining whether patients develop other features of their particular illness. 
Mouth inflammation may predict severity or activation of systemic disease or disease at 
distant sites such as the eye.  
Understanding the nature of this may allow development of preventative treatments or 
strategies to reduce systemic effects of oral inflammation in patients with oral mucosal 
disease. You are unlikely to directly benefit from this research yourself, but we hope 
that the results will benefit patients in the future. 
We require healthy volunteers in order to find out whether the effects of inflammation 
on the mucosa of patients are different to the mucosa of healthy volunteers.  




If you agree to participate in this study you will initially be asked to complete a 
confidential health questionnaire; you will also undergo a physical examination, 
including blood pressure, pulse rate and heart rhythm. We will also require a routine 
blood sample from your arm (about an egg-cup full), a sample of spit (1/2 egg-cup) and 
a urine sample.  
If you are female, we will ask your permission to perform a pregnancy test; as we would 
prefer you not to take part in this study if you are pregnant. None of the tests we intend 
to do will harm an unborn baby, but the skin heals less well in pregnancy and we would 
prefer to avoid surgery in pregnancy unless absolutely necessary. Please inform us if 
you think you may be pregnant. 
There are several components to this study: 
 On entry to the study we will take a blood sample and saliva. The blood sample will be 
taken as part of your routine screen. We will take 50 ml (egg cup full) of blood, 25ml 
(1/2 egg cup of spit) and 10 ml of urine. Blood tests may cause a very small discomfort 
when the needle is put into the vein, but this is momentary. The 25 ml of saliva will be 
taken by asking you to spit into a small container over a period of not more than 5 mins. 
The urine sample will be collected in private. Another two blood tests requiring the 
same amount of blood will be taken over the period of study.  
A small mouth biopsy will be taken from the inside of your cheek or lip. This will be 
6mm (the size of the tip of your small finger). You will be given a pain killing injection 
which will numb the area to be biopsied. This is similar to having an injection at your 
dentist. This painkilling injection does sting, but only momentarily, and it is very 
effective and works quickly. You will not be able to feel any discomfort for the rest of 
the procedure. A stitch will be used to hold the mucosa together afterwards; this will 




frozen and stored prior to examination using molecular or cellular technology. You are 
very unlikely to develop any problems following the above tests. 
Very occasionally, however, a mouth biopsy or a blood test can be associated with 
bruising, bleeding or infection 
If you are female we will ask your permission to perform a pregnancy test, as we would 
prefer you not to take part in this study if you are pregnant. None of these tests will 
harm an unborn baby, but the skin heals less well in pregnancy and we would prefer to 
avoid surgery in pregnancy unless absolutely necessary. Please inform us if you think 
you might be pregnant. 
The above tests will involve you attending either the Royal London Hospital or St. 
Thomas’ Hospital not both (this will depend on the site that you normally attend clinic). 
Tissue samples taken from you may be stored for a period of no more than 5 years, and 
will not be used for any other purposes other than this study. 
Similarly, any blood samples taken from you will only be used for this study. 
If you have any questions concerning this study please feel free to ask us .We can 
provide you with further information if you wish. Contact names and telephone 
numbers are given below.  
You don’t have to join the study. You are free to decide not to be in this trial or to drop 
out at any time.  If you decide not to be in the study, or drop out, this will not put at risk 
your ordinary medical care. 
What happens if you are worried or if there is an emergency? 







Address: Centre for Clinical and Diagnostic Oral Science, Clinical Sciences Building, 2 
Newark Street, London E1 2AT  
Telephone number: 020-7882 7169 
What happens if something goes wrong? 
We believe that this study is basically safe and do not expect you to suffer any harm or 
injury because of your participation in it. However, we carry insurance to make sure that 
if your health does suffer as a result of your being in the study then you will be 
compensated. In such a situation, you will not have to prove that the harm or injury 
which affects you is anyone’s fault. If you are not happy with any proposed 





Appendix 4: Written Consent Form  
 
WRITTEN CONSENT FORM: 
Title of research proposal:      REC Number: 
Name of Patient/Volunteer (Block Capitals): 
Address: 
(Delete if unnecessary to the research project ) 
 The study organisers have invited me to take part in this research.           •  
 I understand what is in the leaflet about the research.  I have a    •  
 copy of the leaflet to keep.  
 I have had the chance to talk and ask questions about the study.     •  
 I know what my part will be in the study and I know how long it will take.       •  
 I have been told about any special drugs, operations, tests or other checks       •  
 I might be given.  
 I know how the study may affect me. I have been told if there are possible risks.      •  
 I understand that I should not actively take part in more than 1 research study at a time.     •  
 I know that the local North East London Health Authority        •  
 Research Ethics Committee has seen and agreed to this study.  
 I understand that personal information is strictly confidential:  I know the       •  
 only people who may see information about my part in the study are the research 
 team or an official representative of the organisation which funded the research. 
   I understand that my personal information may be stored on a computer.  If this      •  
is done then it will not affect the confidentiality of this information.  All such storage 
of information must comply with the 1998 Data Protection Act. 
 I know that the researchers will/might tell my general practitioner (GP)       •  
 about my part in the study. 
 I freely consent to be a subject in the study. No-one has put pressure on me.       •  
 I know that I can stop taking part in the study at any time.       •  
 I know if I do not take part I will still be able to have my normal treatment.       •  




 Refusal to take part will make no difference to the results of my course or my career.       •  
 I know that if there are any problems, I can contact: 
 
 Dr/Mr/Ms.......................................... 
 Tel. No. .............................  Bleep No./Ext. ...................................  
 
Patient’s/Volunteer’s: Signature   ...................................................... 
 
Witness’s signature                                                          ……………………………………. 
 
Title of research proposal:     REC Number: 




















Appendix 5: Clinical Disease activity Forms 
Behçet’s Disease Clinical Activity Information Form 
Date of sample  
Name  
Hospital Number  
Diagnosis: 
Behcet’s Phenotype Active: (tick if applies) Quiet: (tick if applies) 
Mouth   
Genital   
Eyes   
Joints   
Skin: Folliculitis 
          Erythema nodosum 
  
Vascular   
CNS   
GI tract   
Fatigue   
BD Activity Relapse:     Quiet:      
Date of last respiratory tract infection (cold/flu etc): 
Past Medical history: 
Current drugs and Dosage: 
Current smoker?          Y/N             ………. Cigs/day for ………. years 
Past smoker?                Y/N             Date of quitting: 
Ulcer Severity Score:  









Appendix 7: Average expression stability value (M) of reference genes 
 












Appendix 8: Graphs of the remaining Phospho-kinase activities with 
no significant differences 
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